fbpx
Wikipedia

Medical cannabis

February 16, 2024

For other uses of "Cannabis", see Cannabis (disambiguation).
"Medical marijuana" redirects here. For the company, see Medical Marijuana, Inc.

Medical cannabis, or medical marijuana (MMJ), is cannabis and cannabinoids that are prescribed by physicians for their patients.[1][2] The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.[3]

Preliminary evidence has indicated that cannabis might reduce nausea and vomiting during chemotherapy and reduce chronic pain and muscle spasms.[4][5] Regarding non-inhaled cannabis or cannabinoids, a 2021 review found that it provided little relief against chronic pain and sleep disturbance, and caused several transient adverse effects, such as cognitive impairment, nausea, and drowsiness.[6]

Short-term use increases the risk of minor and major adverse effects.[5] Common side effects include dizziness, feeling tired, vomiting, and hallucinations.[5] Long-term effects of cannabis are not clear.[5] Concerns include memory and cognition problems, risk of addiction, schizophrenia in young people, and the risk of children taking it by accident.[4]

Many cultures have used cannabis for therapeutic purposes for thousands of years.[7] Some American medical organizations have requested removal of cannabis from the list of Schedule I controlled substances maintained by the United States federal government, followed by regulatory and scientific review.[8][9] Others oppose its legalization, such as the American Academy of Pediatrics.[10]

Medical cannabis can be administered through various methods, including capsules, lozenges, tinctures, dermal patches, oral or dermal sprays, cannabis edibles, and vaporizing. Synthetic cannabinoids are available for prescription use in some countries, such as dronabinol and nabilone. Countries that allow the medical use of whole-plant cannabis include Argentina, Australia, Canada, Chile, Colombia, Germany, Greece, Israel, Italy, the Netherlands, Peru, Poland, Portugal, Spain, and Uruguay. In the United States, 38 states and the District of Columbia have legalized cannabis for medical purposes, beginning with the passage of California's Proposition 215 in 1996.[11] Although cannabis remains prohibited for any use at the federal level, the Rohrabacher–Farr amendment was enacted in December 2014, limiting the ability of federal law to be enforced in states where medical cannabis has been legalized.

Classification

The National Institute on Drug Abuse defines medical cannabis as "using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions".[12]

A cannabis plant includes more than 400 different chemicals, of which about 70 are cannabinoids.[13] In comparison, typical government-approved medications contain only one or two chemicals.[13] The number of active chemicals in cannabis is one reason why treatment with cannabis is difficult to classify and study.[13]

A 2014 review stated that the variations in ratio of CBD-to-THC in botanical and pharmaceutical preparations determines the therapeutic vs psychoactive effects (CBD attenuates THC's psychoactive effects[14]) of cannabis products.[15]

Medical uses

 
Cannabis as illustrated in Köhler's Book of Medicinal Plants, 1897

Overall, research into the health effects of medical cannabis has been of low quality and it is not clear whether it is a useful treatment for any condition, or whether harms outweigh any benefit.[16] There is no consistent evidence that it helps with chronic pain and muscle spasms.[16]

Low quality evidence suggests its use for reducing nausea during chemotherapy, improving appetite in HIV/AIDS, improving sleep, and improving tics in Tourette syndrome.[5] When usual treatments are ineffective, cannabinoids have also been recommended for anorexia, arthritis, glaucoma,[17] and migraine.[18]

It is unclear whether American states might be able to mitigate the adverse effects of the opioid epidemic by prescribing medical cannabis as an alternative pain management drug.[19]

Cannabis should not be used in pregnancy.[20]

Nausea and vomiting

Medical cannabis is somewhat effective in chemotherapy-induced nausea and vomiting (CINV)[4][17] and may be a reasonable option in those who do not improve following preferential treatment.[21] Comparative studies have found cannabinoids to be more effective than some conventional antiemetics such as prochlorperazine, promethazine, and metoclopramide in controlling CINV,[22] but these are used less frequently because of side effects including dizziness, dysphoria, and hallucinations.[23][24] Long-term cannabis use may cause nausea and vomiting, a condition known as cannabinoid hyperemesis syndrome (CHS).[25]

A 2016 Cochrane review said that cannabinoids were "probably effective" in treating chemotherapy-induced nausea in children, but with a high side-effect profile (mainly drowsiness, dizziness, altered moods, and increased appetite). Less common side effects were "ocular problems, orthostatic hypotension, muscle twitching, pruritus, vagueness, hallucinations, lightheadedness and dry mouth".[26]

HIV/AIDS

Evidence is lacking for both efficacy and safety of cannabis and cannabinoids in treating patients with HIV/AIDS or for anorexia associated with AIDS. As of 2013, current studies suffer from the effects of bias, small sample size, and lack of long-term data.[27]

Pain

A 2021 review found little effect of using non-inhaled cannabis to relieve chronic pain.[6] According to a 2019 systematic review, there have been inconsistent results of using cannabis for neuropathic pain, spasms associated with multiple sclerosis and pain from rheumatic disorders, but was not effective treating chronic cancer pain. The authors state that additional randomized controlled trials of different cannabis products are necessary to make conclusive recommendations.[16]

When cannabis is inhaled to relieve pain, blood levels of cannabinoids rise faster than when oral products are used, peaking within three minutes and attaining an analgesic effect in seven minutes.[28]

A 2011 review considered cannabis to be generally safe,[29] and it appears safer than opioids in palliative care.[30]

A 2022 review concluded the pain relief experienced after using medical cannabis is due to the placebo effect, especially given widespread media attention that sets the expectation for pain relief.[31]

Neurological conditions

Cannabis' efficacy is not clear in treating neurological problems, including multiple sclerosis (MS) and movement problems.[15] Evidence also suggests that oral cannabis extract is effective for reducing patient-centered measures of spasticity.[15] A trial of cannabis is deemed to be a reasonable option if other treatments have not been effective.[4][by whom?] Its use for MS is approved in ten countries.[4][32][conflicted source?] A 2012 review found no problems with tolerance, abuse, or addiction.[33] In the United States, cannabidiol, one of the cannabinoids found in the marijuana plant, has been approved for treating two severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.[34]

Mental disorders

Further information: Posttraumatic stress disorder § Cannabinoids

A 2019 systematic review found that there is a lack of evidence that cannabinoids are effective in treating depressive or anxiety disorders, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder, or psychosis.[35]

Adverse effects

 
American medical hashish

Medical use

There is insufficient data to draw strong conclusions about the safety of medical cannabis.[36] Typically, adverse effects of medical cannabis use are not serious;[4] they include tiredness, dizziness, increased appetite, and cardiovascular and psychoactive effects. Other effects can include impaired short-term memory; impaired motor coordination; altered judgment; and paranoia or psychosis at high doses.[37] Tolerance to these effects develops over a period of days or weeks. The amount of cannabis normally used for medicinal purposes is not believed to cause any permanent cognitive impairment in adults, though long-term treatment in adolescents should be weighed carefully as they are more susceptible to these impairments. Withdrawal symptoms are rarely a problem with controlled medical administration of cannabinoids. The ability to drive vehicles or to operate machinery may be impaired until a tolerance is developed.[21] Although supporters of medical cannabis say that it is safe,[36] further research is required to assess the long-term safety of its use.[23][38]

Cognitive effects

Further information: long-term effects of cannabis

Recreational use of cannabis is associated with cognitive deficits, especially for those who begin to use cannabis in adolescence. As of 2021 there is a lack of research into long-term cognitive effects of medical use of cannabis, but one 12-month observational study reported that "MC patients demonstrated significant improvements on measures of executive function and clinical state over the course of 12 months".[39]

Impact on psychosis

Exposure to THC can cause acute transient psychotic symptoms in healthy individuals and people with schizophrenia.[14]

A 2007 meta analysis concluded that cannabis use reduced the average age of onset of psychosis by 2.7 years relative to non-cannabis use.[40] A 2005 meta analysis concluded that adolescent use of cannabis increases the risk of psychosis, and that the risk is dose-related.[41] A 2004 literature review on the subject concluded that cannabis use is associated with a two-fold increase in the risk of psychosis, but that cannabis use is "neither necessary nor sufficient" to cause psychosis.[42] A French review from 2009 came to a conclusion that cannabis use, particularly that before age 15, was a factor in the development of schizophrenic disorders.[43]

Pharmacology

The genus Cannabis contains two species which produce useful amounts of psychoactive cannabinoids: Cannabis indica and Cannabis sativa, which are listed as Schedule I medicinal plants in the US;[4] a third species, Cannabis ruderalis, has few psychogenic properties.[4] Cannabis contains more than 460 compounds;[7] at least 80 of these are cannabinoids[44][45] – chemical compounds that interact with cannabinoid receptors in the brain.[4] As of 2012, more than 20 cannabinoids were being studied by the U.S. FDA.[46]

The most psychoactive cannabinoid found in the cannabis plant is tetrahydrocannabinol (or delta-9-tetrahydrocannabinol, commonly known as THC).[7] Other cannabinoids include delta-8-tetrahydrocannabinol, cannabidiol (CBD), cannabinol (CBN), cannabicyclol (CBL), cannabichromene (CBC) and cannabigerol (CBG); they have less psychotropic effects than THC, but may play a role in the overall effect of cannabis.[7] The most studied are THC, CBD and CBN.[47]

CB1 and CB2 are the primary cannabinoid receptors responsible for several of the effects of cannabinoids, although other receptors may play a role as well. Both belong to a group of receptors called G protein-coupled receptors (GPCRs). CB1 receptors are found in very high levels in the brain and are thought to be responsible for psychoactive effects.[48] CB2 receptors are found peripherally throughout the body and are thought to modulate pain and inflammation.[49]

Absorption

Cannabinoid absorption is dependent on its route of administration.

Inhaled and vaporized THC have similar absorption profiles to smoked THC, with a bioavailability ranging from 10 to 35%. Oral administration has the lowest bioavailability of approximately 6%, variable absorption depending on the vehicle used, and the longest time to peak plasma levels (2 to 6 hours) compared to smoked or vaporized THC.[50]

Similar to THC, CBD has poor oral bioavailability, approximately 6%. The low bioavailability is largely attributed to significant first-pass metabolism in the liver and erratic absorption from the gastrointestinal tract. However, oral administration of CBD has a faster time to peak concentrations (2 hours) than THC.[50]

Due to the poor bioavailability of oral preparations, alternative routes of administration have been studied, including sublingual and rectal. These alternative formulations maximize bioavailability and reduce first-pass metabolism. Sublingual administration in rabbits yielded bioavailability of 16% and time to peak concentration of 4 hours.[51] Rectal administration in monkeys doubled bioavailability to 13.5% and achieved peak blood concentrations within 1 to 8 hours after administration.[52]

Distribution

Like cannabinoid absorption, distribution is also dependent on route of administration. Smoking and inhalation of vaporized cannabis have better absorption than do other routes of administration, and therefore also have more predictable distribution.[52][53] THC is highly protein bound once absorbed, with only 3% found unbound in the plasma. It distributes rapidly to highly vascularized organs such as the heart, lungs, liver, spleen, and kidneys, as well as to various glands. Low levels can be detected in the brain, testes, and unborn fetuses, all of which are protected from systemic circulation via barriers.[54] THC further distributes into fatty tissues a few days after administration due to its high lipophilicity, and is found deposited in the spleen and fat after redistribution.[53][55][56]

Metabolism

Delta-9-THC is the primary molecule responsible for the effects of cannabis. Delta-9-THC is metabolized in the liver and turns into 11-OH-THC.[57] 11-OH-THC is the first metabolic product in this pathway. Both Delta-9-THC and 11-OH-THC are psychoactive. The metabolism of THC into 11-OH-THC plays a part in the heightened psychoactive effects of edible cannabis.[58]

Next, 11-OH-THC is metabolized in the liver into 11-COOH-THC, which is the second metabolic product of THC.[59] 11-COOH-THC is not psychoactive.[57]

Ingestion of edible cannabis products lead to a slower onset of effect than the inhalation of it because the THC travels to the liver first through the blood before it travels to the rest of the body. Inhaled cannabis can result in THC going directly to the brain, where it then travels from the brain back to the liver in recirculation for metabolism.[57] Eventually, both routes of metabolism result in the metabolism of psychoactive THC to inactive 11-COOH-THC.

Excretion

Due to substantial metabolism of THC and CBD, their metabolites are excreted mostly via feces, rather than by urine.[50][60] After delta-9-THC is hydroxylated into 11-OH-THC via CYP2C9, CYP2C19, and CYP3A4, it undergoes phase II metabolism into more than 30 metabolites, a majority of which are products of glucuronidation. Approximately 65% of THC is excreted in feces and 25% in the urine, while the remaining 10% is excreted by other means.[50] The terminal half-life of THC is 25 to 36 hours,[61] whereas for CBD it is 18 to 32 hours.[60]

CBD is hydroxylated by P450 liver enzymes into 7-OH-CBD. Its metabolites are products of primarily CYP2C19 and CYP3A4 activity, with potential activity of CYP1A1, CYP1A2, CYP2C9, and CYP2D6.[62] Similar to delta-9-THC, a majority of CBD is excreted in feces and some in the urine.[50] The terminal half-life is approximately 18–32 hours.[63]

Administration

 
Illustrating various forms of medicinal cannabis

Smoking has been the means of administration of cannabis for many users, but it is not suitable for the use of cannabis as a medicine.[64] It was the most common method of medical cannabis consumption in the US as of 2013.[4] It is difficult to predict the pharmacological response to cannabis because concentration of cannabinoids varies widely, as there are different ways of preparing it for consumption (smoked, applied as oils, eaten, infused into other foods, or drunk) and a lack of production controls.[4] The potential for adverse effects from smoke inhalation makes smoking a less viable option than oral preparations.[64] Cannabis vaporizers have gained popularity because of a perception among users that fewer harmful chemicals are ingested when components are inhaled via aerosol rather than smoke.[4] Cannabinoid medicines are available in pill form (dronabinol and nabilone) and liquid extracts formulated into an oromucosal spray (nabiximols).[4] Oral preparations are "problematic due to the uptake of cannabinoids into fatty tissue, from which they are released slowly, and the significant first-pass liver metabolism, which breaks down Δ9THC and contributes further to the variability of plasma concentrations".[64]

The US Food and Drug Administration (FDA) has not approved smoked cannabis for any condition or disease, as it deems that evidence is lacking concerning safety and efficacy.[65] The FDA issued a 2006 advisory against smoked medical cannabis stating: "marijuana has a high potential for abuse, has no currently accepted medical use in treatment in the United States, and has a lack of accepted safety for use under medical supervision."[65]

History

Main article: History of medical cannabis

Ancient

Cannabis, called má 麻 (meaning "hemp; cannabis; numbness") or dàmá 大麻 (with "big; great") in Chinese, was used in Taiwan for fiber starting about 10,000 years ago.[66] The botanist Hui-lin Li wrote that in China, "The use of Cannabis in medicine was probably a very early development. Since ancient humans used hemp seed as food, it was quite natural for them to also discover the medicinal properties of the plant."[67] Emperor Shen-Nung, who was also a pharmacologist, wrote a book on treatment methods in 2737 BCE that included the medical benefits of cannabis. He recommended the substance for many ailments, including constipation, gout, rheumatism, and absent-mindedness.[68] Cannabis is one of the 50 "fundamental" herbs in traditional Chinese medicine.[69]

The Ebers Papyrus (c. 1550 BCE) from Ancient Egypt describes medical cannabis.[70] The ancient Egyptians used hemp (cannabis) in suppositories for relieving the pain of hemorrhoids.[71]

Surviving texts from ancient India confirm that cannabis' psychoactive properties were recognized, and doctors used it for treating a variety of illnesses and ailments, including insomnia, headaches, gastrointestinal disorders, and pain, including during childbirth.[72]

The Ancient Greeks used cannabis to dress wounds and sores on their horses,[73] and in humans, dried leaves of cannabis were used to treat nose bleeds, and cannabis seeds were used to expel tapeworms.[73]

In the medieval Islamic world, Arabic physicians made use of the diuretic, antiemetic, antiepileptic, anti-inflammatory, analgesic and antipyretic properties of Cannabis sativa, and used it extensively as medication from the 8th to 18th centuries.[74]

Landrace strains

 
Evolution of cultivated cannabis strains. The cultivar, Cannabis ruderalis, still grows wild today.

Cannabis seeds may have been used for food, rituals or religious practices in ancient Europe and China.[75]: 19–22  Harvesting the plant led to the spread of cannabis throughout Eurasia about 10,000 to 5,000 years ago, with further distribution to the Middle East and Africa about 2,000 to 500 years ago.[75]: 18–19  A landrace strain of cannabis developed over centuries.[76] They are cultivars of the plant that originated in one specific region.

Widely cultivated strains of cannabis, such as "Afghani" or "Hindu Kush", are indigenous to the Pakistan and Afghanistan regions, while "Durban Poison" is native to Africa.[75]: 45–48  There are approximately 16 landrace strains of cannabis identified from Pakistan, Jamaica, Africa, Mexico, Central America and Asia.[77]

Modern

An Irish physician, William Brooke O'Shaughnessy, is credited with introducing cannabis to Western medicine.[78] O'Shaughnessy discovered cannabis in the 1830s while living abroad in India, where he conducted numerous experiments investigating the drug's medical utility (noting in particular its analgesic and anticonvulsant effects).[79] He returned to England with a supply of cannabis in 1842, after which its use spread through Europe and the United States.[80] In 1845 French physician Jacques-Joseph Moreau published a book about the use of cannabis in psychiatry.[81] In 1850 cannabis was entered into the United States Pharmacopeia.[79] An anecdotal report of Cannabis indica as a treatment for tetanus appeared in Scientific American in 1880.[82]

The use of cannabis in medicine began to decline by the end of the 19th century, due to difficulty in controlling dosages and the rise in popularity of synthetic and opium-derived drugs.[80] Also, the advent of the hypodermic syringe allowed these drugs to be injected for immediate effect, in contrast to cannabis which is not water-soluble and therefore cannot be injected.[80]

In the United States, the medical use of cannabis further declined with the passage of the Marihuana Tax Act of 1937, which imposed new regulations and fees on physicians prescribing cannabis.[83] Cannabis was removed from the U.S. Pharmacopeia in 1941, and officially banned for any use with the passage of the Controlled Substances Act of 1970.[80]

Cannabis began to attract renewed interest as medicine in the 1970s and 1980s, in particular due to its use by cancer and AIDS patients who reported relief from the effects of chemotherapy and wasting syndrome.[84] In 1996, California became the first U.S. state to legalize medical cannabis in defiance of federal law.[85] In 2001, Canada became the first country to adopt a system regulating the medical use of cannabis.[86]

  •  
    The use of cannabis, at least as fiber, has been shown to go back at least 10,000 years in Taiwan. "Dà má" (Pinyin pronunciation) is the Chinese expression for cannabis, the first character meaning "big" and the second character meaning "hemp".
  •  
    Cannabis indica fluid extract, American Druggists Syndicate, pre-1937
  •  
    An advertisement for cannabis americana distributed by a pharmacist in New York in 1917
  •  
    The Ebers Papyrus (c. 1550 BCE) from Ancient Egypt has a prescription for medical marijuana applied directly for inflammation.

Society and culture

Legal status

See also: Legality of cannabis by country
 
Legal status of (whole-plant) medical cannabis worldwide
  Legal as authorized by a physician
  Legal for any use (no prescription required)
See also countries that have decriminalized or where enforcement is limited.

Countries that have legalized the medical use of cannabis include Argentina,[87] Australia,[88] Brazil,[89] Canada,[90] Chile,[90] Colombia,[90] Costa Rica,[91] Croatia,[92] Cyprus,[93] Czech Republic,[90] Finland,[94] Germany,[95] Greece,[96] Israel,[97] Italy,[98] Jamaica,[99] Lebanon,[100] Luxembourg,[101] Malta,[102] Morocco,[103] the Netherlands,[90] New Zealand,[104] North Macedonia,[105] Panama,[106] Peru,[107] Poland,[108] Portugal,[109] Rwanda,[110] Spain,[111] Sri Lanka,[112] Switzerland,[113] Thailand,[114] the United Kingdom,[115] and Uruguay.[90] Other countries have more restrictive laws that allow only the use of isolated cannabinoid drugs such as Sativex or Epidiolex.[116][117] Countries with the most relaxed policies include Canada,[118] the Netherlands,[90] Thailand,[119] and Uruguay,[90] where cannabis can be purchased without need for a prescription. In Mexico, THC content of medical cannabis is limited to one percent.[120] In the United States, the legality of medical cannabis varies by state.[11]

Cannabis and its derivatives are subject to regulation under three United Nations treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[121] Cannabis is classified as a Schedule I drug under the Single Convention treaty, meaning that medical use is allowed but that it is considered to be an addictive drug with a serious risk of abuse – along with other drugs such as opium and cocaine.[122] Prior to December 2020 it was also included in Schedule IV, a subset of Schedule I, which is for only the most dangerous drugs such as heroin and fentanyl.[123] Member nations of the UN Commission on Narcotic Drugs voted 27–25 to remove it from Schedule IV on 2 December 2020,[124] following a World Health Organization recommendation for removal in January 2019.[125][126]

United States

See also: Medical cannabis in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia.[11] An additional 10 states have more restrictive laws allowing the use of low-THC products.[11] Cannabis remains illegal at the federal level under the Controlled Substances Act, which classifies it as a Schedule I drug with a high potential for abuse and no accepted medical use. In December 2014, however, the Rohrabacher–Farr amendment was signed into law, prohibiting the Justice Department from prosecuting individuals acting in accordance with state medical cannabis laws.[127]

Economics

Distribution

 
Medical marijuana dispensary in Denver, Colorado

The method of obtaining medical cannabis varies by region and by legislation. In the US, most consumers grow their own or buy it from cannabis dispensaries in states where it is legal.[4][128] Marijuana vending machines for selling or dispensing cannabis are in use in the United States and are planned to be used in Canada.[129] In 2014, the startup Meadow began offering on-demand delivery of medical marijuana in the San Francisco Bay Area, through their mobile app.[130]

Almost 70% of medical cannabis is exported from the United Kingdom, according to a 2017 United Nations report, with much of the remaining amount coming from Canada and the Netherlands.[131]

Insurance

In the United States, health insurance companies may not pay for a medical marijuana prescription as the Food and Drug Administration must approve any substance for medicinal purposes. Before this can happen, the FDA must first permit the study of the medical benefits and drawbacks of the substance, which it has not done since it was placed on Schedule I of the Controlled Substances Act in 1970. Therefore, all expenses incurred fulfilling a medical marijuana prescription will possibly be incurred as out-of-pocket.[132] However, the New Mexico Court of Appeals has ruled that workers' compensation insurance must pay for prescribed marijuana as part of the state's Medical Cannabis Program.[133]

Positions of medical organizations

Medical organizations that have issued statements in support of allowing access to medical cannabis include the American Nurses Association,[8] American Public Health Association,[134] American Medical Student Association,[135] National Multiple Sclerosis Society,[136] Epilepsy Foundation,[137] and Leukemia & Lymphoma Society.[138]

Organizations that oppose the legalization of medical cannabis include the American Academy of Pediatrics[10] and American Psychiatric Association.[139] However, the AAP also supports rescheduling for the purpose of facilitating research.[10]

The American Medical Association[140] and American College of Physicians[141] do not take a position on the legalization of medical cannabis, but have called for the Schedule I classification to be reviewed. The American Academy of Family Physicians[9] and American Society of Addiction Medicine[142] also do not take a position, but do support rescheduling to better facilitate research. The American Heart Association says that "many of the concerning health implications of cannabis include cardiovascular diseases" but that it supports rescheduling to allow "more nuanced ... marijuana legislation and regulation" and to "reflect the existing science behind cannabis".[143] The American Cancer Society[144] and American Psychological Association[145] have noted the obstacles that exist for conducting research on cannabis, and have called on the federal government to better enable scientific study of the drug.

Cancer Research UK say that while cannabis is being studied for therapeutic potential, "claims that there is solid "proof" that cannabis or cannabinoids can cure cancer is highly misleading to patients and their families, and builds a false picture of the state of progress in this area".[146]

Brand names

In the US, the FDA has approved two oral cannabinoids for use as medicine: dronabinol and nabilone.[4] Dronabinol, synthetic THC, is listed as Schedule II.[147] Nabilone, a synthetic cannabinoid, is also Schedule II, indicating high potential for side effects and addiction.[46] Both received approval for sale in the US in 1985, under the brand names Marinol and Cesamet.[148] Nabiximols, an oromucosal spray derived from two strains of Cannabis sativa and containing THC and CBD,[46] is not approved in the United States, but is approved in several European countries, Canada, and New Zealand as of 2013.[4] As of 2018, medical marijuana in Canada is being legally distributed to registered patients in bud, drops and capsule forms by such companies as Canopy Growth Corp. and Aurora Cannabis.

Generic
medication 		Brand
name(s) 		Country Licensed indications
Nabilone Cesamet U.S., Canada Antiemetic (treatment of nausea or vomiting) associated with chemotherapy that has failed to respond adequately to conventional therapy[4]
Dronabinol Marinol
Syndros U.S. Anorexia associated with AIDS–related weight loss[4]
Nabiximols Sativex Canada, New Zealand,
majority of the EU[149]		 Limited treatment for spasticity and neuropathic pain associated with multiple sclerosis and intractable cancer pain.[4]

As an antiemetic, these medications are usually used when conventional treatment for nausea and vomiting associated with cancer chemotherapy fail to work.[4]

Nabiximols is used for treatment of spasticity associated with MS when other therapies have not worked, and when an initial trial demonstrates "meaningful improvement".[4] Trials for FDA approval in the US are underway.[4] It is also approved in several European countries for overactive bladder and vomiting.[46] When sold under the trade name Sativex as a mouth spray, the prescribed daily dose in Sweden delivers a maximum of 32.4 mg of THC and 30 mg of CBD; mild to moderate dizziness is common during the first few weeks.[150]

Relative to inhaled consumption, peak concentration of oral THC is delayed, and it may be difficult to determine optimal dosage because of variability in patient absorption.[4]

In 1964, Albert Lockhart and Manley West began studying the health effects of traditional cannabis use in Jamaican communities. They developed, and in 1987 gained permission to market, the pharmaceutical "Canasol", one of the first cannabis extracts.[151]

Research

Main article: Medical cannabis research

Medical cannabis research includes any medical research on using cannabis as a treatment for any medical condition. For reasons including increased popular support of cannabis use, a trend of cannabis legalization, and the perception of medical usefulness, more scientists are doing medical cannabis research. Medical cannabis is broad for many conditions, each of which has its own state of research.

A 2022 review concluded that "oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation."[152]

See also

References

  1. ^ Murnion B (December 2015). "Medicinal cannabis". Australian Prescriber. 38 (6): 212–15. doi:10.18773/austprescr.2015.072. PMC 4674028. PMID 26843715.
  2. ^ "What is medical marijuana?". National Institute of Drug Abuse. July 2015. from the original on 17 April 2016. Retrieved 19 April 2016. The term medical marijuana refers to using the whole unprocessed marijuana plant or its basic extracts to treat a disease or symptom.
  3. ^ "Release the strains". Nature Medicine. 21 (9): 963. September 2015. doi:10.1038/nm.3946. PMID 26340110.
  4. ^ a b c d e f g h i j k l m n o p q r s t u v w Borgelt LM, Franson KL, Nussbaum AM, Wang GS (February 2013). "The pharmacologic and clinical effects of medical cannabis" (PDF). Pharmacotherapy. 33 (2): 195–209. doi:10.1002/phar.1187. PMID 23386598. S2CID 8503107. (PDF) from the original on 28 August 2021. Retrieved 11 November 2017.
  5. ^ a b c d e Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (23 June 2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis". JAMA. 313 (24): 2456–73. doi:10.1001/jama.2015.6358. hdl:10757/558499. PMID 26103030.
  6. ^ a b Wang, Li; Hong, Patrick J; May, Curtis; Rehman, Yasir; Oparin, Yvgeniy; Hong, Chris J; Hong, Brian Y; AminiLari, Mahmood; Gallo, Lucas (9 September 2021). "Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials". BMJ. 374: n1034. doi:10.1136/bmj.n1034. ISSN 1756-1833. PMID 34497047. from the original on 9 September 2021. Retrieved 9 September 2021.
  7. ^ a b c d Ben Amar M (April 2006). "Cannabinoids in medicine: A review of their therapeutic potential". Journal of Ethnopharmacology (Review). 105 (1–2): 1–25. CiteSeerX 10.1.1.180.308. doi:10.1016/j.jep.2006.02.001. PMID 16540272.
  8. ^ a b Therapeutic Use of Marijuana and Related Cannabinoids (PDF), American Nurses Association, 2016, (PDF) from the original on 21 September 2020, retrieved 13 May 2018
  9. ^ a b "AAFP Releases Marijuana, Cannabinoids Position Paper". American Academy of Family Physicians. 20 September 2019. from the original on 28 September 2019. Retrieved 6 October 2019.
  10. ^ a b c , American Academy of Pediatrics, 26 January 2015, archived from the original on 26 April 2018, retrieved 30 July 2017
  11. ^ a b c d "State Medical Marijuana Laws". National Conference of State Legislatures. 12 September 2022. from the original on 11 December 2018. Retrieved 6 October 2022.
  12. ^ "Marijuana as Medicine". National Institute on Drug Abuse. July 2019. from the original on 17 April 2016. Retrieved 19 April 2016.
  13. ^ a b c Consumer Reports (28 April 2016). "Up in Smoke: Does Medical Marijuana Work?". Consumer Reports. from the original on 14 March 2021. Retrieved 24 May 2016.
  14. ^ a b Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP (January 2014). (PDF). European Neuropsychopharmacology. 24 (1): 51–64. doi:10.1016/j.euroneuro.2013.11.002. PMID 24309088. S2CID 13197304. Archived from the original (PDF) on 20 October 2018. Retrieved 9 July 2016.
  15. ^ a b c Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (April 2014). "Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology". Neurology. 82 (17): 1556–1563. doi:10.1212/WNL.0000000000000363. PMC 4011465. PMID 24778283.
  16. ^ a b c Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, Clemons M, Kanji S, Hutton B (December 2019). "Benefits and harms of medical cannabis: a scoping review of systematic reviews". Syst Rev (Systematic review). 8 (1): 320. doi:10.1186/s13643-019-1243-x. PMC 6905063. PMID 31823819.
  17. ^ a b Sachs J, McGlade E, Yurgelun-Todd D (October 2015). "Safety and Toxicology of Cannabinoids". Neurotherapeutics. 12 (4): 735–46. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
  18. ^ "Sex(ism), Drugs, and Migraines: Distillations Podcast and Transcript, Episode 237". Distillations. Science History Institute. 15 January 2019. from the original on 14 March 2021. Retrieved 28 August 2019.
  19. ^ Gilson, Aaron M.; LeBaron, Virginia T.; Vyas, Marianne Beare (1 January 2018). "The use of cannabis in response to the opioid crisis: A review of the literature". Nursing Outlook. 66 (1): 56–65. doi:10.1016/j.outlook.2017.08.012. ISSN 0029-6554. PMID 28993073.
  20. ^ American College of Obstetricians Gynecologists Committee on Obstetric Practice (July 2015). "Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation". Obstetrics and Gynecology. 126 (1): 234–38. doi:10.1097/01.AOG.0000467192.89321.a6. PMID 26241291.
  21. ^ a b Grotenhermen F, Müller-Vahl K (July 2012). "The therapeutic potential of cannabis and cannabinoids". Deutsches Ärzteblatt International. 109 (29–30): 495–501. doi:10.3238/arztebl.2012.0495. PMC 3442177. PMID 23008748.
  22. ^ Bowles DW, O'Bryant CL, Camidge DR, Jimeno A (July 2012). "The intersection between cannabis and cancer in the United States". Critical Reviews in Oncology/Hematology (Review). 83 (1): 1–10. doi:10.1016/j.critrevonc.2011.09.008. PMID 22019199.
  23. ^ a b Wang T, Collet JP, Shapiro S, Ware MA (June 2008). "Adverse effects of medical cannabinoids: a systematic review". CMAJ (Review). 178 (13): 1669–78. doi:10.1503/cmaj.071178. PMC 2413308. PMID 18559804.
  24. ^ Jordan K, Sippel C, Schmoll HJ (September 2007). (PDF). The Oncologist (Review). 12 (9): 1143–50. doi:10.1634/theoncologist.12-9-1143. PMID 17914084. S2CID 17612434. Archived from the original (PDF) on 7 March 2019.
  25. ^ Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B (May–June 2012). "Cannabinoid hyperemesis syndrome: a case series and review of previous reports". Psychosomatics (Review, case series). 53 (3): 212–19. doi:10.1016/j.psym.2012.01.003. PMID 22480624.
  26. ^ Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, Pizer B (February 2016). "Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood" (PDF). The Cochrane Database of Systematic Reviews. 2016 (2): CD007786. doi:10.1002/14651858.CD007786.pub3. PMC 7073407. PMID 26836199. (PDF) from the original on 30 June 2021. Retrieved 23 September 2019.
  27. ^ Lutge EE, Gray A, Siegfried N (April 2013). "The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS". The Cochrane Database of Systematic Reviews (Review). 4 (4): CD005175. doi:10.1002/14651858.CD005175.pub3. PMID 23633327.
  28. ^ Aviram J, Samuelly-Leichtag G (September 2017). "Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Pain Physician. 20 (6): E755–96. doi:10.36076/ppj.20.5.E755. PMID 28934780. from the original on 30 June 2021. Retrieved 12 January 2018.
  29. ^ Lynch ME, Campbell F (November 2011). "Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials". British Journal of Clinical Pharmacology (Review). 72 (5): 735–44. doi:10.1111/j.1365-2125.2011.03970.x. PMC 3243008. PMID 21426373.
  30. ^ Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L (August 2011). "Cannabis in palliative medicine: improving care and reducing opioid-related morbidity". The American Journal of Hospice & Palliative Care (Review). 28 (5): 297–303. doi:10.1177/1049909111402318. PMID 21444324. S2CID 19980960.
  31. ^ Filip Gedin; Sebastian Blomé; Moa Pontén; Maria Lalouni; Jens Fust; Andreé Raquette; Viktor Vadenmark Lundquist; William H. Thompson; Karin Jensen (28 November 2022). "Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for PainA Systematic Review and Meta-analysis". JAMA Network Open. 5 (11): e2243848. doi:10.1001/jamanetworkopen.2022.43848. PMC 9706362. PMID 36441553.
  32. ^ Clark PA, Capuzzi K, Fick C (December 2011). "Medical marijuana: medical necessity versus political agenda". Medical Science Monitor (Review). 17 (12): RA249–61. doi:10.12659/MSM.882116. PMC 3628147. PMID 22129912.
  33. ^ Oreja-Guevara C (October 2012). "[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]". Revista de Neurología (Review) (in Spanish). 55 (7): 421–30. PMID 23011861.
  34. ^ Commissioner, Office of the (10 June 2019). "FDA and Marijuana". FDA. from the original on 16 November 2019. Retrieved 16 December 2019.
  35. ^ Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". Lancet Psychiatry (Systematic review & meta-analysis). 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. PMC 6949116. PMID 31672337.
  36. ^ a b Washington TA, Brown KM, Fanciullo GJ (2012). "Chapter 31: Medical Cannabis". Pain. Oxford University Press. p. 165. ISBN 978-0-19-994274-9. Proponents of medical cannabis site its safety, but there studies in later years that support that smoking of marijuana is associated with risk for dependence and that THC alters the structures of cells in the brain
  37. ^ Gage SH, Hickman M, Zammit S (April 2016). "Association Between Cannabis and Psychosis: Epidemiologic Evidence". Biological Psychiatry. 79 (7): 549–56. doi:10.1016/j.biopsych.2015.08.001. hdl:1983/b8fb2d3b-5a55-4d07-97c0-1650b0ffc05d. PMID 26386480. S2CID 1055335. from the original on 26 February 2020. Retrieved 11 March 2020.
  38. ^ Barceloux, Donald G (2012). "Chapter 60: Marijuana (Cannabis sativa L.) and synthetic cannabinoids". Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 886–931. ISBN 978-0-471-72760-6. from the original on 13 January 2023. Retrieved 20 December 2015.
  39. ^ Sagar, Kelly A.; Dahlgren, M. Kathryn; Lambros, Ashley M.; Smith, Rosemary T.; El-Abboud, Celine; Gruber, Staci A. (2021). "An Observational, Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment: Preliminary Results". Journal of the International Neuropsychological Society. 27 (6): 648–60. doi:10.1017/S1355617721000114. ISSN 1355-6177. PMID 34261553. S2CID 235824932.
  40. ^ Large M, Sharma S, Compton MT, Slade T, Nielssen O (June 2011). "Cannabis use and earlier onset of psychosis: a systematic meta-analysis". Archives of General Psychiatry. 68 (6): 555–61. doi:10.1001/archgenpsychiatry.2011.5. PMID 21300939.
  41. ^ Semple DM, McIntosh AM, Lawrie SM (March 2005). "Cannabis as a risk factor for psychosis: systematic review". Journal of Psychopharmacology. 19 (2): 187–94. doi:10.1177/0269881105049040. PMID 15871146. S2CID 44651274.
  42. ^ Arseneault L, Cannon M, Witton J, Murray RM (February 2004). "Causal association between cannabis and psychosis: examination of the evidence". The British Journal of Psychiatry. 184 (2): 110–17. doi:10.1192/bjp.184.2.110. PMID 14754822.
  43. ^ Laqueille X (September 2009). "[Is cannabis a vulnerability factor in schizophrenic disorders]" [Is cannabis is a vulnerability factor of schizophrenic disorders?]. Archives de Pédiatrie. 16 (9): 1302–05. doi:10.1016/j.arcped.2009.03.016. PMID 19640690.
  44. ^ Downer EJ, Campbell VA (January 2010). "Phytocannabinoids, CNS cells and development: a dead issue?". Drug and Alcohol Review (Review). 29 (1): 91–98. doi:10.1111/j.1465-3362.2009.00102.x. PMID 20078688.
  45. ^ Burns TL, Ineck JR (February 2006). "Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain". The Annals of Pharmacotherapy (Review). 40 (2): 251–60. doi:10.1345/aph.1G217. PMID 16449552. S2CID 6858360.
  46. ^ a b c d Svrakic DM, Lustman PJ, Mallya A, Lynn TA, Finney R, Svrakic NM (2012). "Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective". Missouri Medicine (Review). 109 (2): 90–98. PMC 6181739. PMID 22675784.
  47. ^ Gordon AJ, Conley JW, Gordon JM (December 2013). "Medical consequences of marijuana use: a review of current literature". Current Psychiatry Reports (Review). 15 (12): 419. doi:10.1007/s11920-013-0419-7. PMID 24234874. S2CID 29063282. from the original on 7 August 2019. Retrieved 12 July 2019.
  48. ^ Mackie K (May 2008). "Cannabinoid receptors: where they are and what they do". Journal of Neuroendocrinology. 20 (Suppl 1): 10–14. doi:10.1111/j.1365-2826.2008.01671.x. PMID 18426493. S2CID 20161611.
  49. ^ Whiteside GT, Lee GP, Valenzano KJ (2007). "The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists". Current Medicinal Chemistry. 14 (8): 917–36. doi:10.2174/092986707780363023. PMID 17430144.
  50. ^ a b c d e Gaston TE, Friedman D (May 2017). "Pharmacology of cannabinoids in the treatment of epilepsy". Epilepsy & Behavior. Cannabinoids and Epilepsy. 70 (Pt B): 313–18. doi:10.1016/j.yebeh.2016.11.016. PMID 28087250. S2CID 3929024.
  51. ^ Mannila J, Järvinen T, Järvinen K, Tervonen J, Jarho P (March 2006). "Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits". Life Sciences. 78 (17): 1911–14. doi:10.1016/j.lfs.2005.08.025. PMID 16266727.
  52. ^ a b Huestis MA (August 2007). "Human cannabinoid pharmacokinetics". Chemistry & Biodiversity. 4 (8): 1770–804. doi:10.1002/cbdv.200790152. PMC 2689518. PMID 17712819.
  53. ^ a b Badowski ME (September 2017). "A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics". Cancer Chemotherapy and Pharmacology. 80 (3): 441–49. doi:10.1007/s00280-017-3387-5. PMC 5573753. PMID 28780725.
  54. ^ Nahas GG (April 2001). "The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking". Human Psychopharmacology. 16 (3): 247–55. doi:10.1002/hup.258. PMID 12404577. S2CID 30513770.
  55. ^ Bridgeman MB, Abazia DT (March 2017). "Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting". P & T. 42 (3): 180–88. PMC 5312634. PMID 28250701.
  56. ^ Nahas GG, Sutin KM, Harvey DJ, Agurell S (1999). Marihuana and Medicine. Springer Science & Business Media. ISBN 978-1-59259-710-9. from the original on 13 January 2023. Retrieved 20 September 2020.
  57. ^ a b c "Human Metabolism of THC". Sapiensoup Blog. 21 December 2016. from the original on 26 June 2021. Retrieved 1 November 2017.
  58. ^ . profofpot.com. 2 July 2016. Archived from the original on 28 June 2021. Retrieved 1 November 2017.
  59. ^ "Toxicology Litigation Support: Marijuana". consultox.com. from the original on 26 June 2021. Retrieved 1 November 2017.
  60. ^ a b Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (June 2014). "Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
  61. ^ Grotenhermen F (1 April 2003). "Pharmacokinetics and pharmacodynamics of cannabinoids". Clinical Pharmacokinetics. 42 (4): 327–60. doi:10.2165/00003088-200342040-00003. PMID 12648025. S2CID 25623600.
  62. ^ Juřica, Ondřej Zendulka, Gabriela Dovrtělová, Kristýna Nosková, Miroslav Turjap, Alexandra Šulcová, Lumír Hanuš and Jan (29 February 2016). "Cannabinoids and Cytochrome P450 Interactions". Current Drug Metabolism. 17 (3): 206–226. doi:10.2174/1389200217666151210142051. PMID 26651971. from the original on 3 July 2021. Retrieved 1 November 2017.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  63. ^ Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (February 1986). "Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration". Biomedical & Environmental Mass Spectrometry. 13 (2): 77–83. doi:10.1002/bms.1200130206. PMID 2937482.
  64. ^ a b c Curtis A, Clarke CE, Rickards HE (October 2009). "Cannabinoids for Tourette's Syndrome". The Cochrane Database of Systematic Reviews (Review). 2009 (4): CD006565. doi:10.1002/14651858.CD006565.pub2. PMC 7387115. PMID 19821373.
  65. ^ a b "Inter-agency advisory regarding claims that smoked marijuana is a medicine" (Press release). fda.gov. 20 April 2006. from the original on 13 October 2012. Retrieved 24 December 2012.
  66. ^ Abel, Ernest L. (1980). "Cannabis in the Ancient World". Marihuana: the first twelve thousand years. New York City: Plenum Publishers. ISBN 978-0-306-40496-2. from the original on 28 June 2021. Retrieved 29 October 2008.[page needed]
  67. ^ Li, Hui-Lin (1974). "An Archaeological and Historical Account of Cannabis in China", Economic Botany 28.4:437–48, p. 444.
  68. ^ Bloomquist, Edward (1971). Marijuana: The Second Trip. California: Glencoe Press.
  69. ^ Wong, Ming (1976). La Médecine chinoise par les plantes. Paris: Tchou. OCLC 2646789.[page needed]
  70. ^ [unreliable source?] . onlinepot.org. Archived from the original on 4 March 2016. Retrieved 10 June 2008.
  71. ^ Pain, Stephanie (15 December 2007). "The Pharaoh's pharmacists". New Scientist. Reed Business Information Ltd. from the original on 21 May 2008. Retrieved 4 September 2017.
  72. ^ Touw M (1981). "The religious and medicinal uses of Cannabis in China, India and Tibet". Journal of Psychoactive Drugs. 13 (1): 23–34. doi:10.1080/02791072.1981.10471447. PMID 7024492.
  73. ^ a b Butrica, James L. (2002). (PDF). Journal of Cannabis Therapeutics. 2 (2): 51–70. doi:10.1300/J175v02n02_04. Archived from the original (PDF) on 11 November 2014. Retrieved 8 November 2014.
  74. ^ Lozano, Indalecio (2001). "The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine". Journal of Cannabis Therapeutics. 1: 63–70. CiteSeerX 10.1.1.550.1717. doi:10.1300/J175v01n01_05.
  75. ^ a b c Holland, Julie, ed. (2010). The Pot Book: A Complete Guide to Cannabis. New York: Simon and Schuster. ISBN 978-1594778988. from the original on 13 January 2023. Retrieved 22 April 2018.
  76. ^ Evert RF, Eichhorn SE (2013). Raven Biology of Plants (8th ed.). New York: W. H. Freeman and Company. pp. 213–17. ISBN 978-1-4292-1961-7.
  77. ^ Evert RF, Eichhorn SE (2013). Raven Biology of Plants (8th ed.). New York: W.H. Freeman and Company. pp. 501–04. ISBN 9781429219617.
  78. ^ Alison Mack; Janet Joy (2000). Marijuana As Medicine?: The Science Beyond the Controversy. National Academies Press. pp. 15–. ISBN 978-0-309-06531-3. from the original on 13 January 2023. Retrieved 20 December 2015.
  79. ^ a b Booth, Martin (2005). Cannabis: A History. New York: St. Martin's Press. ISBN 978-0-312-42494-7.
  80. ^ a b c d Grinspoon L, Bakalar J (1997). Marihuana, the Forbidden Medicine (Revised and expanded ed.). Yale University Press. ISBN 978-0-300-07086-6.
  81. ^ Hans Bangen:Geschichte der medikamentösen Therapie der Schizophrenie. Berlin 1992, p. 22.
  82. ^ Scientific American, "Successful Treatment of Tetanus". Munn & Company. 10 July 1880. p. 25. from the original on 12 January 2023. Retrieved 5 June 2021.
  83. ^ Pacula, Rosalie Piccardo (February 2002). "State Medical Marijuana Laws: Understanding the Laws and Their Limitations" (PDF). Journal of Public Health Policy. 23 (4): 413–39. CiteSeerX 10.1.1.202.2274. doi:10.2307/3343240. JSTOR 3343240. PMID 12532682. S2CID 13389317. (PDF) from the original on 2 March 2021. Retrieved 20 March 2018.
  84. ^ Joy JE, Watson SJ, Benson JA (1999). (PDF). Washington, D.C.: National Academy Press. Archived from the original (PDF) on 23 January 2018. Retrieved 28 July 2017.
  85. ^ "History of Marijuana as Medicine – 2900 BC to Present". ProCon.org. from the original on 15 July 2017. Retrieved 27 July 2017.
  86. ^ "Marijuana's journey to legal health treatment: the Canadian experience". CBC News. 17 August 2009. from the original on 14 June 2017. Retrieved 27 July 2017.
  87. ^ Politi, Daniel (12 November 2020). "Argentina to Allow Medicinal Marijuana to Be Grown at Home". The New York Times. from the original on 23 January 2023. Retrieved 22 January 2023.
  88. ^ Jolly, William (28 February 2018). "Medicinal Marijuana Legal In Australia". Canstar. from the original on 17 July 2018. Retrieved 16 July 2018.
  89. ^ Ponieman, Natan (3 December 2019). "Brazil Regulates Sale Of Medical Marijuana Products". Benzinga. from the original on 14 March 2021. Retrieved 10 December 2019.
  90. ^ a b c d e f g h Williams, Sean (15 May 2016). "10 Countries (Aside From the U.S.) Where Some Form of Medical Marijuana Is Legal". The Motley Fool. from the original on 11 November 2017. Retrieved 5 November 2017.
  91. ^ "Costa Rica legalizes medicinal marijuana use, hemp growing". Associated Press. 2 March 2022. from the original on 7 March 2022. Retrieved 22 January 2023.
  92. ^ Veselica, Lajla (15 October 2015). . Yahoo News. AFP. Archived from the original on 14 March 2021. Retrieved 4 November 2017.
  93. ^ . InCyprus. 22 May 2017. Archived from the original on 9 June 2017. Retrieved 11 November 2017.
  94. ^ "Legal status of cannabis in Finland – An overview". Sensi Seeds. from the original on 14 March 2021. Retrieved 4 November 2017.
  95. ^ Senthilingam, Meera (6 March 2017). "Germany joins the global experiment on marijuana legalization". CNN.com. from the original on 14 March 2021. Retrieved 4 November 2017.
  96. ^ Revesz, Rachael (3 July 2017). "Greece legalises marijuana for medical purposes". The Independent. Archived from the original on 12 May 2022. Retrieved 4 November 2017.
  97. ^ Schwartz, Yardena (24 August 2017). "How the Booming Israeli Weed Industry Is Changing American Pot". Rollingstone.com. from the original on 4 November 2017. Retrieved 4 November 2017.
  98. ^ Samuels, Gabriel (26 July 2016). "Italian army aims to produce "the best-quality" medical marijuana after finding current batches deficient". The Independent. Archived from the original on 12 May 2022. Retrieved 4 November 2017.
  99. ^ Bud, Monterey (19 March 2018). "Jamaica's Kaya Farms Becomes First Medical Marijuana Dispensary To Open". marijuana.com. from the original on 14 March 2021. Retrieved 16 July 2018.
  100. ^ "Lebanon Legalizes Cannabis Farming for Medicinal Use". The New York Times. Reuters. 21 April 2020. from the original on 23 April 2020. Retrieved 25 April 2020.
  101. ^ Pritchard, Heledd (29 June 2018). "Cannabis for medical use legalised in Luxembourg". Luxembourg Times. from the original on 29 June 2018. Retrieved 8 July 2018.
  102. ^ Pace, Maria (27 March 2018). "Malta has officially legalised medical cannabis". Malta Today. from the original on 1 July 2021. Retrieved 24 August 2018.
  103. ^ "Morocco: Bill to legalise cannabis enters into force". Middle East Monitor. 31 July 2021. from the original on 11 August 2021. Retrieved 22 January 2023.
  104. ^ Ainge Roy, Eleanor (11 December 2018). "New Zealand passes laws to make medical marijuana widely available". The Guardian. from the original on 13 January 2019. Retrieved 20 January 2019.
  105. ^ Marusic, Sinisa Jakov (1 June 2016). "Macedonia Allows Medical Marijuana in Pharmacies". Balkan Insight. from the original on 31 October 2017. Retrieved 4 November 2017.
  106. ^ "El gobierno de Panamá legalizó el uso medicinal y terapéutico del cannabis". Infobae. 14 October 2021. from the original on 17 October 2021. Retrieved 22 January 2023.
  107. ^ Collyns, Dan (20 October 2017). "Peru legalises medical marijuana in move spurred by mother's home lab". The Guardian. from the original on 3 July 2018. Retrieved 4 November 2017.
  108. ^ . Radio Poland. PAP. 11 February 2017. Archived from the original on 14 March 2021. Retrieved 4 November 2017.
  109. ^ Lamers, Matt (21 June 2018). "Portugal passes medical cannabis law, opens domestic market". Marijuana Business Daily. from the original on 5 September 2019. Retrieved 24 August 2018.
  110. ^ Mwai, Collins (29 June 2021). "10 things to know after Rwanda gives the green light for medical marijuana". The New Times. from the original on 23 January 2023. Retrieved 22 January 2023.
  111. ^ King, Chris (28 June 2022). "Congress approves the legalisation of medical cannabis in Spain". EuroWeekly News. from the original on 5 December 2022. Retrieved 22 January 2023.
  112. ^ South Asia Regional Profile (PDF), United Nations Office on Drugs and Crime, 15 September 2005, (PDF) from the original on 23 September 2020, retrieved 2 February 2019
  113. ^ . The Local. 28 July 2022. Archived from the original on 9 August 2022. Retrieved 22 January 2023.
  114. ^ Mosbergen, Dominique (25 December 2018). "Thailand Approves Medical Marijuana In Regional First". HuffPost. from the original on 19 January 2019. Retrieved 20 January 2019.
  115. ^ "Medicinal cannabis products to be legalised". BBC. 26 July 2018. from the original on 28 July 2018. Retrieved 28 July 2018.
  116. ^ . GW Pharmaceuticals. Archived from the original on 10 December 2017. Retrieved 5 November 2017.
  117. ^ Medical use of cannabis and cannabinoids (PDF), European Monitoring Centre for Drugs and Drug Addiction, December 2018, (PDF) from the original on 28 June 2021, retrieved 11 December 2019
  118. ^ Sapra, Bani (20 June 2018). "Canada becomes second nation in the world to legalize marijuana". CNN. from the original on 12 February 2019. Retrieved 3 July 2018.
  119. ^ Ives, Mike (10 November 2022). . The New York Times. Archived from the original on 27 November 2022. Retrieved 22 January 2023.
  120. ^ Janikian, Michelle (14 September 2017). "Legal Pot In Mexico: Everything You Need to Know". Rolling Stone. from the original on 11 November 2017. Retrieved 5 November 2017.
  121. ^ Habibi, Roojin; Hoffman, Steven J. (March 2018). "Legalizing Cannabis Violates the UN Drug Control Treaties, But Progressive Countries Like Canada Have Options". Ottawa Law Review. 49 (2). from the original on 28 August 2021. Retrieved 8 January 2021.
  122. ^ "Classification of controlled drugs". European Monitoring Centre for Drugs and Drug Addiction. from the original on 8 January 2021. Retrieved 7 January 2021.
  123. ^ Kaur, Harmeet (2 December 2020). "The UN removes cannabis from a list of the most dangerous substances". CNN. from the original on 12 December 2020. Retrieved 7 January 2021.
  124. ^ Kwai, Isabella (2 December 2020). "U.N. Reclassifies Cannabis as a Less Dangerous Drug". The New York Times. from the original on 10 January 2021. Retrieved 7 January 2021.
  125. ^ "WHO recommends rescheduling of cannabis". European Monitoring Centre for Drugs and Drug Addiction. 25 March 2019. from the original on 28 December 2020. Retrieved 7 January 2021.
  126. ^ Georgiou, Aristos (8 February 2019). "WHO Recommends Rescheduling Cannabis in International Law for First Time in History". Newsweek. from the original on 20 December 2020. Retrieved 7 January 2021.
  127. ^ Ingraham, Christopher (13 June 2017). "Jeff Sessions personally asked Congress to let him prosecute medical-marijuana providers". The Washington Post. from the original on 4 July 2017. Retrieved 9 July 2017.
  128. ^ Timothy B. Wheeler (11 October 2014). . The Baltimore Sun. Archived from the original on 16 October 2014. Retrieved 12 October 2014.
  129. ^ Blackwell, Tom (16 October 2013). "The pot vending machine's first foreign market? Canada, of course, "a seed for the rest of the world"". National Post. Retrieved 4 December 2013.
  130. ^ "Uber-For-Weed Startup Meadow Lights Up In San Francisco". TechCrunch. AOL. 14 October 2014. from the original on 23 January 2016. Retrieved 22 January 2016.
  131. ^ "The UK is the world's largest producer of legal Cannabis, UN body finds". The Independent. 7 March 2018. Archived from the original on 12 May 2022. Retrieved 7 December 2020.
  132. ^ Clark, Tonya Body (10 February 2015). . Compliance Corner. Wolters Kluwer Financial Services. Archived from the original on 26 February 2015. Retrieved 26 February 2015.
  133. ^ Peters, Joey (29 June 2015). "Court: Employer can't block workers' comp for medical marijuana". NM Political Report. from the original on 30 June 2015. Retrieved 30 June 2015.
  134. ^ "Resolution on Medical Marijuana". druglibrary.org. from the original on 19 October 2017. Retrieved 30 July 2017.
  135. ^ "House of Delegates 2017, Resolution: A8" (PDF). amsa.org. American Medical Student Association. (PDF) from the original on 1 August 2017. Retrieved 30 July 2017.
  136. ^ "Medical Marijuana (Cannabis) FAQs". National Multiple Sclerosis Society. from the original on 31 July 2017. Retrieved 30 July 2017.
  137. ^ Gattone PM, Lammert W (20 February 2014). "Epilepsy Foundation Calls for Increased Medical Marijuana Access and Research" (Press release). Washington, D.C.: Epilepsy Foundation. from the original on 31 July 2017. Retrieved 30 July 2017.
  138. ^ "Medical Marijuana Use and Research" (PDF). maps.org. Leukemia & Lymphoma Society. (PDF) from the original on 19 October 2017. Retrieved 30 July 2017.
  139. ^ (PDF). American Psychiatric Association. Archived from the original (PDF) on 31 July 2017. Retrieved 30 July 2017.
  140. ^ (PDF), American Medical Association, 2009, archived from the original (PDF) on 19 October 2017, retrieved 1 July 2017
  141. ^ Supporting Research into the Therapeutic Role of Marijuana (PDF), American College of Physicians, February 2016, (PDF) from the original on 3 August 2020, retrieved 1 August 2017
  142. ^ (Press release). Rockville, MD: American Society of Addiction Medicine. 13 October 2020. Archived from the original on 8 November 2020. Retrieved 1 November 2020.
  143. ^ American Heart Association (5 August 2020). "Medical Marijuana, Recreational Cannabis, and Cardiovascular Health". Circulation. 142 (10): e131–52. doi:10.1161/CIR.0000000000000883. PMID 32752884.
  144. ^ "Marijuana and Cancer". American Cancer Society. from the original on 22 June 2017. Retrieved 12 July 2017.
  145. ^ . American Psychological Association. 14 September 2017. Archived from the original on 4 October 2017. Retrieved 9 October 2017.
  146. ^ Arney, Kat (25 July 2012). . Cancer Research UK. Archived from the original on 11 February 2014.
  147. ^ . U.S. Department of Justice. Archived from the original on 28 March 2018. Retrieved 2 February 2018.
  148. ^ Clark, Amy (16 May 2006). ""New" Pot Pill For Chemo Patients". CBS News. Associated Press. from the original on 28 July 2017. Retrieved 26 July 2017.
  149. ^ Abuhasira R, Shbiro L, Landschaft Y (March 2018). "Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America". European Journal of Internal Medicine. 49: 2–6. doi:10.1016/j.ejim.2018.01.001. PMID 29329891.
  150. ^ "Produkt – FASS Allmänhet". fass.se. from the original on 19 October 2017. Retrieved 26 December 2013.
  151. ^ Youssef, Farid F. (June 2010). "Cannabis Unmasked: What it is and why it does what it does". UWIToday. from the original on 17 March 2021. Retrieved 11 May 2021.
  152. ^ McDonagh MS, Morasco BJ, Wagner J, et al. (2022). "Cannabis-Based Products for Chronic Pain: A Systematic Review". Ann Intern Med. 175 (8): 1143–1153. doi:10.7326/M21-4520. PMID 35667066. S2CID 249433147. from the original on 19 February 2023. Retrieved 19 February 2023.

Further reading

  • National Academies Of Sciences, Engineering; Health Medicine, Division; Board on Population Health Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review Research Agenda (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies of Sciences, Engineering, and Medicine: The National Academies Press. doi:10.17226/24625. ISBN 978-0-309-45304-2. PMID 28182367. from the original on 14 July 2020. Retrieved 7 February 2017. {{cite book}}: |website= ignored (help)  

External links

 
Wikimedia Commons has media related to Medical cannabis.
  • Medical cannabis at Curlie, links to websites about medical cannabis
  • Information on Cannabis and Cannabinoids from the U.S. National Cancer Institute
  • Information on cannabis (marihuana, marijuana) and the cannabinoids from Health Canada
  • Medical Marijuana – a 2014–2015 three-part CNN documentary produced by Sanjay Gupta
  • Marijuana and Medical Marijuana collected news and commentary at The New York Times

February 16, 2024
medical, cannabis, other, uses, cannabis, cannabis, disambiguation, medical, marijuana, redirects, here, company, medical, marijuana, medical, marijuana, cannabis, cannabinoids, that, prescribed, physicians, their, patients, cannabis, medicine, been, rigorousl. For other uses of Cannabis see Cannabis disambiguation Medical marijuana redirects here For the company see Medical Marijuana Inc Medical cannabis or medical marijuana MMJ is cannabis and cannabinoids that are prescribed by physicians for their patients 1 2 The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases 3 Preliminary evidence has indicated that cannabis might reduce nausea and vomiting during chemotherapy and reduce chronic pain and muscle spasms 4 5 Regarding non inhaled cannabis or cannabinoids a 2021 review found that it provided little relief against chronic pain and sleep disturbance and caused several transient adverse effects such as cognitive impairment nausea and drowsiness 6 Short term use increases the risk of minor and major adverse effects 5 Common side effects include dizziness feeling tired vomiting and hallucinations 5 Long term effects of cannabis are not clear 5 Concerns include memory and cognition problems risk of addiction schizophrenia in young people and the risk of children taking it by accident 4 Many cultures have used cannabis for therapeutic purposes for thousands of years 7 Some American medical organizations have requested removal of cannabis from the list of Schedule I controlled substances maintained by the United States federal government followed by regulatory and scientific review 8 9 Others oppose its legalization such as the American Academy of Pediatrics 10 Medical cannabis can be administered through various methods including capsules lozenges tinctures dermal patches oral or dermal sprays cannabis edibles and vaporizing Synthetic cannabinoids are available for prescription use in some countries such as dronabinol and nabilone Countries that allow the medical use of whole plant cannabis include Argentina Australia Canada Chile Colombia Germany Greece Israel Italy the Netherlands Peru Poland Portugal Spain and Uruguay In the United States 38 states and the District of Columbia have legalized cannabis for medical purposes beginning with the passage of California s Proposition 215 in 1996 11 Although cannabis remains prohibited for any use at the federal level the Rohrabacher Farr amendment was enacted in December 2014 limiting the ability of federal law to be enforced in states where medical cannabis has been legalized Contents 1 Classification 2 Medical uses 2 1 Nausea and vomiting 2 2 HIV AIDS 2 3 Pain 2 4 Neurological conditions 2 5 Mental disorders 3 Adverse effects 3 1 Medical use 3 2 Cognitive effects 3 3 Impact on psychosis 4 Pharmacology 4 1 Absorption 4 2 Distribution 4 3 Metabolism 4 4 Excretion 5 Administration 6 History 6 1 Ancient 6 2 Landrace strains 6 3 Modern 7 Society and culture 7 1 Legal status 7 1 1 United States 7 2 Economics 7 2 1 Distribution 7 2 2 Insurance 7 3 Positions of medical organizations 7 4 Brand names 8 Research 9 See also 10 References 11 Further reading 12 External linksClassificationThe National Institute on Drug Abuse defines medical cannabis as using the whole unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions 12 A cannabis plant includes more than 400 different chemicals of which about 70 are cannabinoids 13 In comparison typical government approved medications contain only one or two chemicals 13 The number of active chemicals in cannabis is one reason why treatment with cannabis is difficult to classify and study 13 A 2014 review stated that the variations in ratio of CBD to THC in botanical and pharmaceutical preparations determines the therapeutic vs psychoactive effects CBD attenuates THC s psychoactive effects 14 of cannabis products 15 Medical uses nbsp Cannabis as illustrated in Kohler s Book of Medicinal Plants 1897Overall research into the health effects of medical cannabis has been of low quality and it is not clear whether it is a useful treatment for any condition or whether harms outweigh any benefit 16 There is no consistent evidence that it helps with chronic pain and muscle spasms 16 Low quality evidence suggests its use for reducing nausea during chemotherapy improving appetite in HIV AIDS improving sleep and improving tics in Tourette syndrome 5 When usual treatments are ineffective cannabinoids have also been recommended for anorexia arthritis glaucoma 17 and migraine 18 It is unclear whether American states might be able to mitigate the adverse effects of the opioid epidemic by prescribing medical cannabis as an alternative pain management drug 19 Cannabis should not be used in pregnancy 20 Nausea and vomiting Medical cannabis is somewhat effective in chemotherapy induced nausea and vomiting CINV 4 17 and may be a reasonable option in those who do not improve following preferential treatment 21 Comparative studies have found cannabinoids to be more effective than some conventional antiemetics such as prochlorperazine promethazine and metoclopramide in controlling CINV 22 but these are used less frequently because of side effects including dizziness dysphoria and hallucinations 23 24 Long term cannabis use may cause nausea and vomiting a condition known as cannabinoid hyperemesis syndrome CHS 25 A 2016 Cochrane review said that cannabinoids were probably effective in treating chemotherapy induced nausea in children but with a high side effect profile mainly drowsiness dizziness altered moods and increased appetite Less common side effects were ocular problems orthostatic hypotension muscle twitching pruritus vagueness hallucinations lightheadedness and dry mouth 26 HIV AIDS Evidence is lacking for both efficacy and safety of cannabis and cannabinoids in treating patients with HIV AIDS or for anorexia associated with AIDS As of 2013 current studies suffer from the effects of bias small sample size and lack of long term data 27 Pain A 2021 review found little effect of using non inhaled cannabis to relieve chronic pain 6 According to a 2019 systematic review there have been inconsistent results of using cannabis for neuropathic pain spasms associated with multiple sclerosis and pain from rheumatic disorders but was not effective treating chronic cancer pain The authors state that additional randomized controlled trials of different cannabis products are necessary to make conclusive recommendations 16 When cannabis is inhaled to relieve pain blood levels of cannabinoids rise faster than when oral products are used peaking within three minutes and attaining an analgesic effect in seven minutes 28 A 2011 review considered cannabis to be generally safe 29 and it appears safer than opioids in palliative care 30 A 2022 review concluded the pain relief experienced after using medical cannabis is due to the placebo effect especially given widespread media attention that sets the expectation for pain relief 31 Neurological conditions Cannabis efficacy is not clear in treating neurological problems including multiple sclerosis MS and movement problems 15 Evidence also suggests that oral cannabis extract is effective for reducing patient centered measures of spasticity 15 A trial of cannabis is deemed to be a reasonable option if other treatments have not been effective 4 by whom Its use for MS is approved in ten countries 4 32 conflicted source A 2012 review found no problems with tolerance abuse or addiction 33 In the United States cannabidiol one of the cannabinoids found in the marijuana plant has been approved for treating two severe forms of epilepsy Lennox Gastaut syndrome and Dravet syndrome 34 Mental disorders Further information Posttraumatic stress disorder Cannabinoids A 2019 systematic review found that there is a lack of evidence that cannabinoids are effective in treating depressive or anxiety disorders attention deficit hyperactivity disorder ADHD Tourette syndrome post traumatic stress disorder or psychosis 35 Adverse effects nbsp American medical hashishMedical use There is insufficient data to draw strong conclusions about the safety of medical cannabis 36 Typically adverse effects of medical cannabis use are not serious 4 they include tiredness dizziness increased appetite and cardiovascular and psychoactive effects Other effects can include impaired short term memory impaired motor coordination altered judgment and paranoia or psychosis at high doses 37 Tolerance to these effects develops over a period of days or weeks The amount of cannabis normally used for medicinal purposes is not believed to cause any permanent cognitive impairment in adults though long term treatment in adolescents should be weighed carefully as they are more susceptible to these impairments Withdrawal symptoms are rarely a problem with controlled medical administration of cannabinoids The ability to drive vehicles or to operate machinery may be impaired until a tolerance is developed 21 Although supporters of medical cannabis say that it is safe 36 further research is required to assess the long term safety of its use 23 38 Cognitive effects Further information long term effects of cannabis Recreational use of cannabis is associated with cognitive deficits especially for those who begin to use cannabis in adolescence As of 2021 update there is a lack of research into long term cognitive effects of medical use of cannabis but one 12 month observational study reported that MC patients demonstrated significant improvements on measures of executive function and clinical state over the course of 12 months 39 Impact on psychosis Exposure to THC can cause acute transient psychotic symptoms in healthy individuals and people with schizophrenia 14 A 2007 meta analysis concluded that cannabis use reduced the average age of onset of psychosis by 2 7 years relative to non cannabis use 40 A 2005 meta analysis concluded that adolescent use of cannabis increases the risk of psychosis and that the risk is dose related 41 A 2004 literature review on the subject concluded that cannabis use is associated with a two fold increase in the risk of psychosis but that cannabis use is neither necessary nor sufficient to cause psychosis 42 A French review from 2009 came to a conclusion that cannabis use particularly that before age 15 was a factor in the development of schizophrenic disorders 43 PharmacologyThe genus Cannabis contains two species which produce useful amounts of psychoactive cannabinoids Cannabis indica and Cannabis sativa which are listed as Schedule I medicinal plants in the US 4 a third species Cannabis ruderalis has few psychogenic properties 4 Cannabis contains more than 460 compounds 7 at least 80 of these are cannabinoids 44 45 chemical compounds that interact with cannabinoid receptors in the brain 4 As of 2012 more than 20 cannabinoids were being studied by the U S FDA 46 The most psychoactive cannabinoid found in the cannabis plant is tetrahydrocannabinol or delta 9 tetrahydrocannabinol commonly known as THC 7 Other cannabinoids include delta 8 tetrahydrocannabinol cannabidiol CBD cannabinol CBN cannabicyclol CBL cannabichromene CBC and cannabigerol CBG they have less psychotropic effects than THC but may play a role in the overall effect of cannabis 7 The most studied are THC CBD and CBN 47 CB1 and CB2 are the primary cannabinoid receptors responsible for several of the effects of cannabinoids although other receptors may play a role as well Both belong to a group of receptors called G protein coupled receptors GPCRs CB1 receptors are found in very high levels in the brain and are thought to be responsible for psychoactive effects 48 CB2 receptors are found peripherally throughout the body and are thought to modulate pain and inflammation 49 Absorption Cannabinoid absorption is dependent on its route of administration Inhaled and vaporized THC have similar absorption profiles to smoked THC with a bioavailability ranging from 10 to 35 Oral administration has the lowest bioavailability of approximately 6 variable absorption depending on the vehicle used and the longest time to peak plasma levels 2 to 6 hours compared to smoked or vaporized THC 50 Similar to THC CBD has poor oral bioavailability approximately 6 The low bioavailability is largely attributed to significant first pass metabolism in the liver and erratic absorption from the gastrointestinal tract However oral administration of CBD has a faster time to peak concentrations 2 hours than THC 50 Due to the poor bioavailability of oral preparations alternative routes of administration have been studied including sublingual and rectal These alternative formulations maximize bioavailability and reduce first pass metabolism Sublingual administration in rabbits yielded bioavailability of 16 and time to peak concentration of 4 hours 51 Rectal administration in monkeys doubled bioavailability to 13 5 and achieved peak blood concentrations within 1 to 8 hours after administration 52 Distribution Like cannabinoid absorption distribution is also dependent on route of administration Smoking and inhalation of vaporized cannabis have better absorption than do other routes of administration and therefore also have more predictable distribution 52 53 THC is highly protein bound once absorbed with only 3 found unbound in the plasma It distributes rapidly to highly vascularized organs such as the heart lungs liver spleen and kidneys as well as to various glands Low levels can be detected in the brain testes and unborn fetuses all of which are protected from systemic circulation via barriers 54 THC further distributes into fatty tissues a few days after administration due to its high lipophilicity and is found deposited in the spleen and fat after redistribution 53 55 56 Metabolism Delta 9 THC is the primary molecule responsible for the effects of cannabis Delta 9 THC is metabolized in the liver and turns into 11 OH THC 57 11 OH THC is the first metabolic product in this pathway Both Delta 9 THC and 11 OH THC are psychoactive The metabolism of THC into 11 OH THC plays a part in the heightened psychoactive effects of edible cannabis 58 Next 11 OH THC is metabolized in the liver into 11 COOH THC which is the second metabolic product of THC 59 11 COOH THC is not psychoactive 57 Ingestion of edible cannabis products lead to a slower onset of effect than the inhalation of it because the THC travels to the liver first through the blood before it travels to the rest of the body Inhaled cannabis can result in THC going directly to the brain where it then travels from the brain back to the liver in recirculation for metabolism 57 Eventually both routes of metabolism result in the metabolism of psychoactive THC to inactive 11 COOH THC Excretion Due to substantial metabolism of THC and CBD their metabolites are excreted mostly via feces rather than by urine 50 60 After delta 9 THC is hydroxylated into 11 OH THC via CYP2C9 CYP2C19 and CYP3A4 it undergoes phase II metabolism into more than 30 metabolites a majority of which are products of glucuronidation Approximately 65 of THC is excreted in feces and 25 in the urine while the remaining 10 is excreted by other means 50 The terminal half life of THC is 25 to 36 hours 61 whereas for CBD it is 18 to 32 hours 60 CBD is hydroxylated by P450 liver enzymes into 7 OH CBD Its metabolites are products of primarily CYP2C19 and CYP3A4 activity with potential activity of CYP1A1 CYP1A2 CYP2C9 and CYP2D6 62 Similar to delta 9 THC a majority of CBD is excreted in feces and some in the urine 50 The terminal half life is approximately 18 32 hours 63 Administration nbsp Illustrating various forms of medicinal cannabisSmoking has been the means of administration of cannabis for many users but it is not suitable for the use of cannabis as a medicine 64 It was the most common method of medical cannabis consumption in the US as of 2013 update 4 It is difficult to predict the pharmacological response to cannabis because concentration of cannabinoids varies widely as there are different ways of preparing it for consumption smoked applied as oils eaten infused into other foods or drunk and a lack of production controls 4 The potential for adverse effects from smoke inhalation makes smoking a less viable option than oral preparations 64 Cannabis vaporizers have gained popularity because of a perception among users that fewer harmful chemicals are ingested when components are inhaled via aerosol rather than smoke 4 Cannabinoid medicines are available in pill form dronabinol and nabilone and liquid extracts formulated into an oromucosal spray nabiximols 4 Oral preparations are problematic due to the uptake of cannabinoids into fatty tissue from which they are released slowly and the significant first pass liver metabolism which breaks down D9THC and contributes further to the variability of plasma concentrations 64 The US Food and Drug Administration FDA has not approved smoked cannabis for any condition or disease as it deems that evidence is lacking concerning safety and efficacy 65 The FDA issued a 2006 advisory against smoked medical cannabis stating marijuana has a high potential for abuse has no currently accepted medical use in treatment in the United States and has a lack of accepted safety for use under medical supervision 65 HistoryMain article History of medical cannabis Ancient Cannabis called ma 麻 meaning hemp cannabis numbness or dama 大麻 with big great in Chinese was used in Taiwan for fiber starting about 10 000 years ago 66 The botanist Hui lin Li wrote that in China The use of Cannabis in medicine was probably a very early development Since ancient humans used hemp seed as food it was quite natural for them to also discover the medicinal properties of the plant 67 Emperor Shen Nung who was also a pharmacologist wrote a book on treatment methods in 2737 BCE that included the medical benefits of cannabis He recommended the substance for many ailments including constipation gout rheumatism and absent mindedness 68 Cannabis is one of the 50 fundamental herbs in traditional Chinese medicine 69 The Ebers Papyrus c 1550 BCE from Ancient Egypt describes medical cannabis 70 The ancient Egyptians used hemp cannabis in suppositories for relieving the pain of hemorrhoids 71 Surviving texts from ancient India confirm that cannabis psychoactive properties were recognized and doctors used it for treating a variety of illnesses and ailments including insomnia headaches gastrointestinal disorders and pain including during childbirth 72 The Ancient Greeks used cannabis to dress wounds and sores on their horses 73 and in humans dried leaves of cannabis were used to treat nose bleeds and cannabis seeds were used to expel tapeworms 73 In the medieval Islamic world Arabic physicians made use of the diuretic antiemetic antiepileptic anti inflammatory analgesic and antipyretic properties of Cannabis sativa and used it extensively as medication from the 8th to 18th centuries 74 Landrace strains nbsp Evolution of cultivated cannabis strains The cultivar Cannabis ruderalis still grows wild today Cannabis seeds may have been used for food rituals or religious practices in ancient Europe and China 75 19 22 Harvesting the plant led to the spread of cannabis throughout Eurasia about 10 000 to 5 000 years ago with further distribution to the Middle East and Africa about 2 000 to 500 years ago 75 18 19 A landrace strain of cannabis developed over centuries 76 They are cultivars of the plant that originated in one specific region Widely cultivated strains of cannabis such as Afghani or Hindu Kush are indigenous to the Pakistan and Afghanistan regions while Durban Poison is native to Africa 75 45 48 There are approximately 16 landrace strains of cannabis identified from Pakistan Jamaica Africa Mexico Central America and Asia 77 Modern An Irish physician William Brooke O Shaughnessy is credited with introducing cannabis to Western medicine 78 O Shaughnessy discovered cannabis in the 1830s while living abroad in India where he conducted numerous experiments investigating the drug s medical utility noting in particular its analgesic and anticonvulsant effects 79 He returned to England with a supply of cannabis in 1842 after which its use spread through Europe and the United States 80 In 1845 French physician Jacques Joseph Moreau published a book about the use of cannabis in psychiatry 81 In 1850 cannabis was entered into the United States Pharmacopeia 79 An anecdotal report of Cannabis indica as a treatment for tetanus appeared in Scientific American in 1880 82 The use of cannabis in medicine began to decline by the end of the 19th century due to difficulty in controlling dosages and the rise in popularity of synthetic and opium derived drugs 80 Also the advent of the hypodermic syringe allowed these drugs to be injected for immediate effect in contrast to cannabis which is not water soluble and therefore cannot be injected 80 In the United States the medical use of cannabis further declined with the passage of the Marihuana Tax Act of 1937 which imposed new regulations and fees on physicians prescribing cannabis 83 Cannabis was removed from the U S Pharmacopeia in 1941 and officially banned for any use with the passage of the Controlled Substances Act of 1970 80 Cannabis began to attract renewed interest as medicine in the 1970s and 1980s in particular due to its use by cancer and AIDS patients who reported relief from the effects of chemotherapy and wasting syndrome 84 In 1996 California became the first U S state to legalize medical cannabis in defiance of federal law 85 In 2001 Canada became the first country to adopt a system regulating the medical use of cannabis 86 nbsp The use of cannabis at least as fiber has been shown to go back at least 10 000 years in Taiwan Da ma Pinyin pronunciation is the Chinese expression for cannabis the first character meaning big and the second character meaning hemp nbsp Cannabis indica fluid extract American Druggists Syndicate pre 1937 nbsp An advertisement for cannabis americana distributed by a pharmacist in New York in 1917 nbsp The Ebers Papyrus c 1550 BCE from Ancient Egypt has a prescription for medical marijuana applied directly for inflammation Society and cultureLegal status See also Legality of cannabis by country nbsp Legal status of whole plant medical cannabis worldwide Legal as authorized by a physician Legal for any use no prescription required See also countries that have decriminalized or where enforcement is limited Countries that have legalized the medical use of cannabis include Argentina 87 Australia 88 Brazil 89 Canada 90 Chile 90 Colombia 90 Costa Rica 91 Croatia 92 Cyprus 93 Czech Republic 90 Finland 94 Germany 95 Greece 96 Israel 97 Italy 98 Jamaica 99 Lebanon 100 Luxembourg 101 Malta 102 Morocco 103 the Netherlands 90 New Zealand 104 North Macedonia 105 Panama 106 Peru 107 Poland 108 Portugal 109 Rwanda 110 Spain 111 Sri Lanka 112 Switzerland 113 Thailand 114 the United Kingdom 115 and Uruguay 90 Other countries have more restrictive laws that allow only the use of isolated cannabinoid drugs such as Sativex or Epidiolex 116 117 Countries with the most relaxed policies include Canada 118 the Netherlands 90 Thailand 119 and Uruguay 90 where cannabis can be purchased without need for a prescription In Mexico THC content of medical cannabis is limited to one percent 120 In the United States the legality of medical cannabis varies by state 11 Cannabis and its derivatives are subject to regulation under three United Nations treaties the 1961 Single Convention on Narcotic Drugs the 1971 Convention on Psychotropic Substances and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 121 Cannabis is classified as a Schedule I drug under the Single Convention treaty meaning that medical use is allowed but that it is considered to be an addictive drug with a serious risk of abuse along with other drugs such as opium and cocaine 122 Prior to December 2020 it was also included in Schedule IV a subset of Schedule I which is for only the most dangerous drugs such as heroin and fentanyl 123 Member nations of the UN Commission on Narcotic Drugs voted 27 25 to remove it from Schedule IV on 2 December 2020 124 following a World Health Organization recommendation for removal in January 2019 125 126 United States See also Medical cannabis in the United States In the United States the use of cannabis for medical purposes is legal in 38 states four out of five permanently inhabited U S territories and the District of Columbia 11 An additional 10 states have more restrictive laws allowing the use of low THC products 11 Cannabis remains illegal at the federal level under the Controlled Substances Act which classifies it as a Schedule I drug with a high potential for abuse and no accepted medical use In December 2014 however the Rohrabacher Farr amendment was signed into law prohibiting the Justice Department from prosecuting individuals acting in accordance with state medical cannabis laws 127 Economics Distribution nbsp Medical marijuana dispensary in Denver ColoradoThe method of obtaining medical cannabis varies by region and by legislation In the US most consumers grow their own or buy it from cannabis dispensaries in states where it is legal 4 128 Marijuana vending machines for selling or dispensing cannabis are in use in the United States and are planned to be used in Canada 129 In 2014 the startup Meadow began offering on demand delivery of medical marijuana in the San Francisco Bay Area through their mobile app 130 Almost 70 of medical cannabis is exported from the United Kingdom according to a 2017 United Nations report with much of the remaining amount coming from Canada and the Netherlands 131 Insurance In the United States health insurance companies may not pay for a medical marijuana prescription as the Food and Drug Administration must approve any substance for medicinal purposes Before this can happen the FDA must first permit the study of the medical benefits and drawbacks of the substance which it has not done since it was placed on Schedule I of the Controlled Substances Act in 1970 Therefore all expenses incurred fulfilling a medical marijuana prescription will possibly be incurred as out of pocket 132 However the New Mexico Court of Appeals has ruled that workers compensation insurance must pay for prescribed marijuana as part of the state s Medical Cannabis Program 133 Positions of medical organizations Medical organizations that have issued statements in support of allowing access to medical cannabis include the American Nurses Association 8 American Public Health Association 134 American Medical Student Association 135 National Multiple Sclerosis Society 136 Epilepsy Foundation 137 and Leukemia amp Lymphoma Society 138 Organizations that oppose the legalization of medical cannabis include the American Academy of Pediatrics 10 and American Psychiatric Association 139 However the AAP also supports rescheduling for the purpose of facilitating research 10 The American Medical Association 140 and American College of Physicians 141 do not take a position on the legalization of medical cannabis but have called for the Schedule I classification to be reviewed The American Academy of Family Physicians 9 and American Society of Addiction Medicine 142 also do not take a position but do support rescheduling to better facilitate research The American Heart Association says that many of the concerning health implications of cannabis include cardiovascular diseases but that it supports rescheduling to allow more nuanced marijuana legislation and regulation and to reflect the existing science behind cannabis 143 The American Cancer Society 144 and American Psychological Association 145 have noted the obstacles that exist for conducting research on cannabis and have called on the federal government to better enable scientific study of the drug Cancer Research UK say that while cannabis is being studied for therapeutic potential claims that there is solid proof that cannabis or cannabinoids can cure cancer is highly misleading to patients and their families and builds a false picture of the state of progress in this area 146 Brand names In the US the FDA has approved two oral cannabinoids for use as medicine dronabinol and nabilone 4 Dronabinol synthetic THC is listed as Schedule II 147 Nabilone a synthetic cannabinoid is also Schedule II indicating high potential for side effects and addiction 46 Both received approval for sale in the US in 1985 under the brand names Marinol and Cesamet 148 Nabiximols an oromucosal spray derived from two strains of Cannabis sativa and containing THC and CBD 46 is not approved in the United States but is approved in several European countries Canada and New Zealand as of 2013 4 As of 2018 medical marijuana in Canada is being legally distributed to registered patients in bud drops and capsule forms by such companies as Canopy Growth Corp and Aurora Cannabis Genericmedication Brand name s Country Licensed indicationsNabilone Cesamet U S Canada Antiemetic treatment of nausea or vomiting associated with chemotherapy that has failed to respond adequately to conventional therapy 4 Dronabinol MarinolSyndros U S Anorexia associated with AIDS related weight loss 4 Nabiximols Sativex Canada New Zealand majority of the EU 149 Limited treatment for spasticity and neuropathic pain associated with multiple sclerosis and intractable cancer pain 4 As an antiemetic these medications are usually used when conventional treatment for nausea and vomiting associated with cancer chemotherapy fail to work 4 Nabiximols is used for treatment of spasticity associated with MS when other therapies have not worked and when an initial trial demonstrates meaningful improvement 4 Trials for FDA approval in the US are underway 4 It is also approved in several European countries for overactive bladder and vomiting 46 When sold under the trade name Sativex as a mouth spray the prescribed daily dose in Sweden delivers a maximum of 32 4 mg of THC and 30 mg of CBD mild to moderate dizziness is common during the first few weeks 150 Relative to inhaled consumption peak concentration of oral THC is delayed and it may be difficult to determine optimal dosage because of variability in patient absorption 4 In 1964 Albert Lockhart and Manley West began studying the health effects of traditional cannabis use in Jamaican communities They developed and in 1987 gained permission to market the pharmaceutical Canasol one of the first cannabis extracts 151 ResearchMain article Medical cannabis research Medical cannabis research includes any medical research on using cannabis as a treatment for any medical condition For reasons including increased popular support of cannabis use a trend of cannabis legalization and the perception of medical usefulness more scientists are doing medical cannabis research Medical cannabis is broad for many conditions each of which has its own state of research A 2022 review concluded that oral synthetic cannabis products with high THC to CBD ratios and sublingual extracted cannabis products with comparable THC to CBD ratios may be associated with short term improvements in chronic pain and increased risk for dizziness and sedation 152 See also nbsp Cannabis portal nbsp Medicine portalCharlotte s Web cannabis Chinese herbology Tilden s ExtractReferences Murnion B December 2015 Medicinal cannabis Australian Prescriber 38 6 212 15 doi 10 18773 austprescr 2015 072 PMC 4674028 PMID 26843715 What is medical marijuana National Institute of Drug Abuse July 2015 Archived from the original on 17 April 2016 Retrieved 19 April 2016 The term medical marijuana refers to using the whole unprocessed marijuana plant or its basic extracts to treat a disease or symptom Release the strains Nature Medicine 21 9 963 September 2015 doi 10 1038 nm 3946 PMID 26340110 a b c d e f g h i j k l m n o p q r s t u v w Borgelt LM Franson KL Nussbaum AM Wang GS February 2013 The pharmacologic and clinical effects of medical cannabis PDF Pharmacotherapy 33 2 195 209 doi 10 1002 phar 1187 PMID 23386598 S2CID 8503107 Archived PDF from the original on 28 August 2021 Retrieved 11 November 2017 a b c d e Whiting PF Wolff RF Deshpande S Di Nisio M Duffy S Hernandez AV Keurentjes JC Lang S Misso K Ryder S Schmidlkofer S Westwood M Kleijnen J 23 June 2015 Cannabinoids for Medical Use A Systematic Review and Meta analysis JAMA 313 24 2456 73 doi 10 1001 jama 2015 6358 hdl 10757 558499 PMID 26103030 a b Wang Li Hong Patrick J May Curtis Rehman Yasir Oparin Yvgeniy Hong Chris J Hong Brian Y AminiLari Mahmood Gallo Lucas 9 September 2021 Medical cannabis or cannabinoids for chronic non cancer and cancer related pain a systematic review and meta analysis of randomised clinical trials BMJ 374 n1034 doi 10 1136 bmj n1034 ISSN 1756 1833 PMID 34497047 Archived from the original on 9 September 2021 Retrieved 9 September 2021 a b c d Ben Amar M April 2006 Cannabinoids in medicine A review of their therapeutic potential Journal of Ethnopharmacology Review 105 1 2 1 25 CiteSeerX 10 1 1 180 308 doi 10 1016 j jep 2006 02 001 PMID 16540272 a b Therapeutic Use of Marijuana and Related Cannabinoids PDF American Nurses Association 2016 archived PDF from the original on 21 September 2020 retrieved 13 May 2018 a b AAFP Releases Marijuana Cannabinoids Position Paper American Academy of Family Physicians 20 September 2019 Archived from the original on 28 September 2019 Retrieved 6 October 2019 a b c American Academy of Pediatrics Reaffirms Opposition to Legalizing Marijuana for Recreational or Medical Use American Academy of Pediatrics 26 January 2015 archived from the original on 26 April 2018 retrieved 30 July 2017 a b c d State Medical Marijuana Laws National Conference of State Legislatures 12 September 2022 Archived from the original on 11 December 2018 Retrieved 6 October 2022 Marijuana as Medicine National Institute on Drug Abuse July 2019 Archived from the original on 17 April 2016 Retrieved 19 April 2016 a b c Consumer Reports 28 April 2016 Up in Smoke Does Medical Marijuana Work Consumer Reports Archived from the original on 14 March 2021 Retrieved 24 May 2016 a b Schubart CD Sommer IE Fusar Poli P de Witte L Kahn RS Boks MP January 2014 Cannabidiol as a potential treatment for psychosis PDF European Neuropsychopharmacology 24 1 51 64 doi 10 1016 j euroneuro 2013 11 002 PMID 24309088 S2CID 13197304 Archived from the original PDF on 20 October 2018 Retrieved 9 July 2016 a b c Koppel BS Brust JC Fife T Bronstein J Youssof S Gronseth G Gloss D April 2014 Systematic review efficacy and safety of medical marijuana in selected neurologic disorders report of the Guideline Development Subcommittee of the American Academy of Neurology Neurology 82 17 1556 1563 doi 10 1212 WNL 0000000000000363 PMC 4011465 PMID 24778283 a b c Pratt M Stevens A Thuku M Butler C Skidmore B Wieland LS Clemons M Kanji S Hutton B December 2019 Benefits and harms of medical cannabis a scoping review of systematic reviews Syst Rev Systematic review 8 1 320 doi 10 1186 s13643 019 1243 x PMC 6905063 PMID 31823819 a b Sachs J McGlade E Yurgelun Todd D October 2015 Safety and Toxicology of Cannabinoids Neurotherapeutics 12 4 735 46 doi 10 1007 s13311 015 0380 8 PMC 4604177 PMID 26269228 Sex ism Drugs and Migraines Distillations Podcast and Transcript Episode 237 Distillations Science History Institute 15 January 2019 Archived from the original on 14 March 2021 Retrieved 28 August 2019 Gilson Aaron M LeBaron Virginia T Vyas Marianne Beare 1 January 2018 The use of cannabis in response to the opioid crisis A review of the literature Nursing Outlook 66 1 56 65 doi 10 1016 j outlook 2017 08 012 ISSN 0029 6554 PMID 28993073 American College of Obstetricians Gynecologists Committee on Obstetric Practice July 2015 Committee Opinion No 637 Marijuana Use During Pregnancy and Lactation Obstetrics and Gynecology 126 1 234 38 doi 10 1097 01 AOG 0000467192 89321 a6 PMID 26241291 a b Grotenhermen F Muller Vahl K July 2012 The therapeutic potential of cannabis and cannabinoids Deutsches Arzteblatt International 109 29 30 495 501 doi 10 3238 arztebl 2012 0495 PMC 3442177 PMID 23008748 Bowles DW O Bryant CL Camidge DR Jimeno A July 2012 The intersection between cannabis and cancer in the United States Critical Reviews in Oncology Hematology Review 83 1 1 10 doi 10 1016 j critrevonc 2011 09 008 PMID 22019199 a b Wang T Collet JP Shapiro S Ware MA June 2008 Adverse effects of medical cannabinoids a systematic review CMAJ Review 178 13 1669 78 doi 10 1503 cmaj 071178 PMC 2413308 PMID 18559804 Jordan K Sippel C Schmoll HJ September 2007 Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting past present and future recommendations PDF The Oncologist Review 12 9 1143 50 doi 10 1634 theoncologist 12 9 1143 PMID 17914084 S2CID 17612434 Archived from the original PDF on 7 March 2019 Nicolson SE Denysenko L Mulcare JL Vito JP Chabon B May June 2012 Cannabinoid hyperemesis syndrome a case series and review of previous reports Psychosomatics Review case series 53 3 212 19 doi 10 1016 j psym 2012 01 003 PMID 22480624 Phillips RS Friend AJ Gibson F Houghton E Gopaul S Craig JV Pizer B February 2016 Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood PDF The Cochrane Database of Systematic Reviews 2016 2 CD007786 doi 10 1002 14651858 CD007786 pub3 PMC 7073407 PMID 26836199 Archived PDF from the original on 30 June 2021 Retrieved 23 September 2019 Lutge EE Gray A Siegfried N April 2013 The medical use of cannabis for reducing morbidity and mortality in patients with HIV AIDS The Cochrane Database of Systematic Reviews Review 4 4 CD005175 doi 10 1002 14651858 CD005175 pub3 PMID 23633327 Aviram J Samuelly Leichtag G September 2017 Efficacy of Cannabis Based Medicines for Pain Management A Systematic Review and Meta Analysis of Randomized Controlled Trials Pain Physician 20 6 E755 96 doi 10 36076 ppj 20 5 E755 PMID 28934780 Archived from the original on 30 June 2021 Retrieved 12 January 2018 Lynch ME Campbell F November 2011 Cannabinoids for treatment of chronic non cancer pain a systematic review of randomized trials British Journal of Clinical Pharmacology Review 72 5 735 44 doi 10 1111 j 1365 2125 2011 03970 x PMC 3243008 PMID 21426373 Carter GT Flanagan AM Earleywine M Abrams DI Aggarwal SK Grinspoon L August 2011 Cannabis in palliative medicine improving care and reducing opioid related morbidity The American Journal of Hospice amp Palliative Care Review 28 5 297 303 doi 10 1177 1049909111402318 PMID 21444324 S2CID 19980960 Filip Gedin Sebastian Blome Moa Ponten Maria Lalouni Jens Fust Andree Raquette Viktor Vadenmark Lundquist William H Thompson Karin Jensen 28 November 2022 Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis Based Therapies for PainA Systematic Review and Meta analysis JAMA Network Open 5 11 e2243848 doi 10 1001 jamanetworkopen 2022 43848 PMC 9706362 PMID 36441553 Clark PA Capuzzi K Fick C December 2011 Medical marijuana medical necessity versus political agenda Medical Science Monitor Review 17 12 RA249 61 doi 10 12659 MSM 882116 PMC 3628147 PMID 22129912 Oreja Guevara C October 2012 Treatment of spasticity in multiple sclerosis new perspectives regarding the use of cannabinoids Revista de Neurologia Review in Spanish 55 7 421 30 PMID 23011861 Commissioner Office of the 10 June 2019 FDA and Marijuana FDA Archived from the original on 16 November 2019 Retrieved 16 December 2019 Black N Stockings E Campbell G Tran LT Zagic D Hall WD Farrell M Degenhardt L 2019 Cannabinoids for the treatment of mental disorders and symptoms of mental disorders a systematic review and meta analysis Lancet Psychiatry Systematic review amp meta analysis 6 12 995 1010 doi 10 1016 S2215 0366 19 30401 8 PMC 6949116 PMID 31672337 a b Washington TA Brown KM Fanciullo GJ 2012 Chapter 31 Medical Cannabis Pain Oxford University Press p 165 ISBN 978 0 19 994274 9 Proponents of medical cannabis site its safety but there studies in later years that support that smoking of marijuana is associated with risk for dependence and that THC alters the structures of cells in the brain Gage SH Hickman M Zammit S April 2016 Association Between Cannabis and Psychosis Epidemiologic Evidence Biological Psychiatry 79 7 549 56 doi 10 1016 j biopsych 2015 08 001 hdl 1983 b8fb2d3b 5a55 4d07 97c0 1650b0ffc05d PMID 26386480 S2CID 1055335 Archived from the original on 26 February 2020 Retrieved 11 March 2020 Barceloux Donald G 2012 Chapter 60 Marijuana Cannabis sativa L and synthetic cannabinoids Medical Toxicology of Drug Abuse Synthesized Chemicals and Psychoactive Plants John Wiley amp Sons pp 886 931 ISBN 978 0 471 72760 6 Archived from the original on 13 January 2023 Retrieved 20 December 2015 Sagar Kelly A Dahlgren M Kathryn Lambros Ashley M Smith Rosemary T El Abboud Celine Gruber Staci A 2021 An Observational Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment Preliminary Results Journal of the International Neuropsychological Society 27 6 648 60 doi 10 1017 S1355617721000114 ISSN 1355 6177 PMID 34261553 S2CID 235824932 Large M Sharma S Compton MT Slade T Nielssen O June 2011 Cannabis use and earlier onset of psychosis a systematic meta analysis Archives of General Psychiatry 68 6 555 61 doi 10 1001 archgenpsychiatry 2011 5 PMID 21300939 Semple DM McIntosh AM Lawrie SM March 2005 Cannabis as a risk factor for psychosis systematic review Journal of Psychopharmacology 19 2 187 94 doi 10 1177 0269881105049040 PMID 15871146 S2CID 44651274 Arseneault L Cannon M Witton J Murray RM February 2004 Causal association between cannabis and psychosis examination of the evidence The British Journal of Psychiatry 184 2 110 17 doi 10 1192 bjp 184 2 110 PMID 14754822 Laqueille X September 2009 Is cannabis a vulnerability factor in schizophrenic disorders Is cannabis is a vulnerability factor of schizophrenic disorders Archives de Pediatrie 16 9 1302 05 doi 10 1016 j arcped 2009 03 016 PMID 19640690 Downer EJ Campbell VA January 2010 Phytocannabinoids CNS cells and development a dead issue Drug and Alcohol Review Review 29 1 91 98 doi 10 1111 j 1465 3362 2009 00102 x PMID 20078688 Burns TL Ineck JR February 2006 Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain The Annals of Pharmacotherapy Review 40 2 251 60 doi 10 1345 aph 1G217 PMID 16449552 S2CID 6858360 a b c d Svrakic DM Lustman PJ Mallya A Lynn TA Finney R Svrakic NM 2012 Legalization decriminalization amp medicinal use of cannabis a scientific and public health perspective Missouri Medicine Review 109 2 90 98 PMC 6181739 PMID 22675784 Gordon AJ Conley JW Gordon JM December 2013 Medical consequences of marijuana use a review of current literature Current Psychiatry Reports Review 15 12 419 doi 10 1007 s11920 013 0419 7 PMID 24234874 S2CID 29063282 Archived from the original on 7 August 2019 Retrieved 12 July 2019 Mackie K May 2008 Cannabinoid receptors where they are and what they do Journal of Neuroendocrinology 20 Suppl 1 10 14 doi 10 1111 j 1365 2826 2008 01671 x PMID 18426493 S2CID 20161611 Whiteside GT Lee GP Valenzano KJ 2007 The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists Current Medicinal Chemistry 14 8 917 36 doi 10 2174 092986707780363023 PMID 17430144 a b c d e Gaston TE Friedman D May 2017 Pharmacology of cannabinoids in the treatment of epilepsy Epilepsy amp Behavior Cannabinoids and Epilepsy 70 Pt B 313 18 doi 10 1016 j yebeh 2016 11 016 PMID 28087250 S2CID 3929024 Mannila J Jarvinen T Jarvinen K Tervonen J Jarho P March 2006 Sublingual administration of Delta9 tetrahydrocannabinol beta cyclodextrin complex increases the bioavailability of Delta9 tetrahydrocannabinol in rabbits Life Sciences 78 17 1911 14 doi 10 1016 j lfs 2005 08 025 PMID 16266727 a b Huestis MA August 2007 Human cannabinoid pharmacokinetics Chemistry amp Biodiversity 4 8 1770 804 doi 10 1002 cbdv 200790152 PMC 2689518 PMID 17712819 a b Badowski ME September 2017 A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy induced nausea and vomiting a focus on pharmacokinetic variability and pharmacodynamics Cancer Chemotherapy and Pharmacology 80 3 441 49 doi 10 1007 s00280 017 3387 5 PMC 5573753 PMID 28780725 Nahas GG April 2001 The pharmacokinetics of THC in fat and brain resulting functional responses to marihuana smoking Human Psychopharmacology 16 3 247 55 doi 10 1002 hup 258 PMID 12404577 S2CID 30513770 Bridgeman MB Abazia DT March 2017 Medicinal Cannabis History Pharmacology And Implications for the Acute Care Setting P amp T 42 3 180 88 PMC 5312634 PMID 28250701 Nahas GG Sutin KM Harvey DJ Agurell S 1999 Marihuana and Medicine Springer Science amp Business Media ISBN 978 1 59259 710 9 Archived from the original on 13 January 2023 Retrieved 20 September 2020 a b c Human Metabolism of THC Sapiensoup Blog 21 December 2016 Archived from the original on 26 June 2021 Retrieved 1 November 2017 11 Hydroxy THC Increased Potency That Explains the Effect of Edibles Prof of Pot profofpot com 2 July 2016 Archived from the original on 28 June 2021 Retrieved 1 November 2017 Toxicology Litigation Support Marijuana consultox com Archived from the original on 26 June 2021 Retrieved 1 November 2017 a b Devinsky O Cilio MR Cross H Fernandez Ruiz J French J Hill C Katz R Di Marzo V Jutras Aswad D Notcutt WG Martinez Orgado J Robson PJ Rohrback BG Thiele E Whalley B Friedman D June 2014 Cannabidiol pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Epilepsia 55 6 791 802 doi 10 1111 epi 12631 PMC 4707667 PMID 24854329 Grotenhermen F 1 April 2003 Pharmacokinetics and pharmacodynamics of cannabinoids Clinical Pharmacokinetics 42 4 327 60 doi 10 2165 00003088 200342040 00003 PMID 12648025 S2CID 25623600 Jurica Ondrej Zendulka Gabriela Dovrtelova Kristyna Noskova Miroslav Turjap Alexandra Sulcova Lumir Hanus and Jan 29 February 2016 Cannabinoids and Cytochrome P450 Interactions Current Drug Metabolism 17 3 206 226 doi 10 2174 1389200217666151210142051 PMID 26651971 Archived from the original on 3 July 2021 Retrieved 1 November 2017 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Ohlsson A Lindgren JE Andersson S Agurell S Gillespie H Hollister LE February 1986 Single dose kinetics of deuterium labelled cannabidiol in man after smoking and intravenous administration Biomedical amp Environmental Mass Spectrometry 13 2 77 83 doi 10 1002 bms 1200130206 PMID 2937482 a b c Curtis A Clarke CE Rickards HE October 2009 Cannabinoids for Tourette s Syndrome The Cochrane Database of Systematic Reviews Review 2009 4 CD006565 doi 10 1002 14651858 CD006565 pub2 PMC 7387115 PMID 19821373 a b Inter agency advisory regarding claims that smoked marijuana is a medicine Press release fda gov 20 April 2006 Archived from the original on 13 October 2012 Retrieved 24 December 2012 Abel Ernest L 1980 Cannabis in the Ancient World Marihuana the first twelve thousand years New York City Plenum Publishers ISBN 978 0 306 40496 2 Archived from the original on 28 June 2021 Retrieved 29 October 2008 page needed Li Hui Lin 1974 An Archaeological and Historical Account of Cannabis in China Economic Botany 28 4 437 48 p 444 Bloomquist Edward 1971 Marijuana The Second Trip California Glencoe Press Wong Ming 1976 La Medecine chinoise par les plantes Paris Tchou OCLC 2646789 page needed unreliable source The Ebers Papyrus The Oldest confirmed Written Prescriptions For Medical Marihuana era 1 550 BC onlinepot org Archived from the original on 4 March 2016 Retrieved 10 June 2008 Pain Stephanie 15 December 2007 The Pharaoh s pharmacists New Scientist Reed Business Information Ltd Archived from the original on 21 May 2008 Retrieved 4 September 2017 Touw M 1981 The religious and medicinal uses of Cannabis in China India and Tibet Journal of Psychoactive Drugs 13 1 23 34 doi 10 1080 02791072 1981 10471447 PMID 7024492 a b Butrica James L 2002 The Medical Use of Cannabis Among the Greeks and Romans PDF Journal of Cannabis Therapeutics 2 2 51 70 doi 10 1300 J175v02n02 04 Archived from the original PDF on 11 November 2014 Retrieved 8 November 2014 Lozano Indalecio 2001 The Therapeutic Use of Cannabis sativa L in Arabic Medicine Journal of Cannabis Therapeutics 1 63 70 CiteSeerX 10 1 1 550 1717 doi 10 1300 J175v01n01 05 a b c Holland Julie ed 2010 The Pot Book A Complete Guide to Cannabis New York Simon and Schuster ISBN 978 1594778988 Archived from the original on 13 January 2023 Retrieved 22 April 2018 Evert RF Eichhorn SE 2013 Raven Biology of Plants 8th ed New York W H Freeman and Company pp 213 17 ISBN 978 1 4292 1961 7 Evert RF Eichhorn SE 2013 Raven Biology of Plants 8th ed New York W H Freeman and Company pp 501 04 ISBN 9781429219617 Alison Mack Janet Joy 2000 Marijuana As Medicine The Science Beyond the Controversy National Academies Press pp 15 ISBN 978 0 309 06531 3 Archived from the original on 13 January 2023 Retrieved 20 December 2015 a b Booth Martin 2005 Cannabis A History New York St Martin s Press ISBN 978 0 312 42494 7 a b c d Grinspoon L Bakalar J 1997 Marihuana the Forbidden Medicine Revised and expanded ed Yale University Press ISBN 978 0 300 07086 6 Hans Bangen Geschichte der medikamentosen Therapie der Schizophrenie Berlin 1992 p 22 Scientific American Successful Treatment of Tetanus Munn amp Company 10 July 1880 p 25 Archived from the original on 12 January 2023 Retrieved 5 June 2021 Pacula Rosalie Piccardo February 2002 State Medical Marijuana Laws Understanding the Laws and Their Limitations PDF Journal of Public Health Policy 23 4 413 39 CiteSeerX 10 1 1 202 2274 doi 10 2307 3343240 JSTOR 3343240 PMID 12532682 S2CID 13389317 Archived PDF from the original on 2 March 2021 Retrieved 20 March 2018 Joy JE Watson SJ Benson JA 1999 Marijuana and Medicine Assessing the Science Base PDF Washington D C National Academy Press Archived from the original PDF on 23 January 2018 Retrieved 28 July 2017 History of Marijuana as Medicine 2900 BC to Present ProCon org Archived from the original on 15 July 2017 Retrieved 27 July 2017 Marijuana s journey to legal health treatment the Canadian experience CBC News 17 August 2009 Archived from the original on 14 June 2017 Retrieved 27 July 2017 Politi Daniel 12 November 2020 Argentina to Allow Medicinal Marijuana to Be Grown at Home The New York Times Archived from the original on 23 January 2023 Retrieved 22 January 2023 Jolly William 28 February 2018 Medicinal Marijuana Legal In Australia Canstar Archived from the original on 17 July 2018 Retrieved 16 July 2018 Ponieman Natan 3 December 2019 Brazil Regulates Sale Of Medical Marijuana Products Benzinga Archived from the original on 14 March 2021 Retrieved 10 December 2019 a b c d e f g h Williams Sean 15 May 2016 10 Countries Aside From the U S Where Some Form of Medical Marijuana Is Legal The Motley Fool Archived from the original on 11 November 2017 Retrieved 5 November 2017 Costa Rica legalizes medicinal marijuana use hemp growing Associated Press 2 March 2022 Archived from the original on 7 March 2022 Retrieved 22 January 2023 Veselica Lajla 15 October 2015 Croatia legalises marijuana for medical use Yahoo News AFP Archived from the original on 14 March 2021 Retrieved 4 November 2017 Cyprus begins to distribute medical cannabis InCyprus 22 May 2017 Archived from the original on 9 June 2017 Retrieved 11 November 2017 Legal status of cannabis in Finland An overview Sensi Seeds Archived from the original on 14 March 2021 Retrieved 4 November 2017 Senthilingam Meera 6 March 2017 Germany joins the global experiment on marijuana legalization CNN com Archived from the original on 14 March 2021 Retrieved 4 November 2017 Revesz Rachael 3 July 2017 Greece legalises marijuana for medical purposes The Independent Archived from the original on 12 May 2022 Retrieved 4 November 2017 Schwartz Yardena 24 August 2017 How the Booming Israeli Weed Industry Is Changing American Pot Rollingstone com Archived from the original on 4 November 2017 Retrieved 4 November 2017 Samuels Gabriel 26 July 2016 Italian army aims to produce the best quality medical marijuana after finding current batches deficient The Independent Archived from the original on 12 May 2022 Retrieved 4 November 2017 Bud Monterey 19 March 2018 Jamaica s Kaya Farms Becomes First Medical Marijuana Dispensary To Open marijuana com Archived from the original on 14 March 2021 Retrieved 16 July 2018 Lebanon Legalizes Cannabis Farming for Medicinal Use The New York Times Reuters 21 April 2020 Archived from the original on 23 April 2020 Retrieved 25 April 2020 Pritchard Heledd 29 June 2018 Cannabis for medical use legalised in Luxembourg Luxembourg Times Archived from the original on 29 June 2018 Retrieved 8 July 2018 Pace Maria 27 March 2018 Malta has officially legalised medical cannabis Malta Today Archived from the original on 1 July 2021 Retrieved 24 August 2018 Morocco Bill to legalise cannabis enters into force Middle East Monitor 31 July 2021 Archived from the original on 11 August 2021 Retrieved 22 January 2023 Ainge Roy Eleanor 11 December 2018 New Zealand passes laws to make medical marijuana widely available The Guardian Archived from the original on 13 January 2019 Retrieved 20 January 2019 Marusic Sinisa Jakov 1 June 2016 Macedonia Allows Medical Marijuana in Pharmacies Balkan Insight Archived from the original on 31 October 2017 Retrieved 4 November 2017 El gobierno de Panama legalizo el uso medicinal y terapeutico del cannabis Infobae 14 October 2021 Archived from the original on 17 October 2021 Retrieved 22 January 2023 Collyns Dan 20 October 2017 Peru legalises medical marijuana in move spurred by mother s home lab The Guardian Archived from the original on 3 July 2018 Retrieved 4 November 2017 Medical use of cannabis officially legal in Poland Radio Poland PAP 11 February 2017 Archived from the original on 14 March 2021 Retrieved 4 November 2017 Lamers Matt 21 June 2018 Portugal passes medical cannabis law opens domestic market Marijuana Business Daily Archived from the original on 5 September 2019 Retrieved 24 August 2018 Mwai Collins 29 June 2021 10 things to know after Rwanda gives the green light for medical marijuana The New Times Archived from the original on 23 January 2023 Retrieved 22 January 2023 King Chris 28 June 2022 Congress approves the legalisation of medical cannabis in Spain EuroWeekly News Archived from the original on 5 December 2022 Retrieved 22 January 2023 South Asia Regional Profile PDF United Nations Office on Drugs and Crime 15 September 2005 archived PDF from the original on 23 September 2020 retrieved 2 February 2019 Switzerland to legalise medicinal cannabis from Monday The Local 28 July 2022 Archived from the original on 9 August 2022 Retrieved 22 January 2023 Mosbergen Dominique 25 December 2018 Thailand Approves Medical Marijuana In Regional First HuffPost Archived from the original on 19 January 2019 Retrieved 20 January 2019 Medicinal cannabis products to be legalised BBC 26 July 2018 Archived from the original on 28 July 2018 Retrieved 28 July 2018 Sativex delta 9 tetrahydrocannabinol and cannabidiol GW Pharmaceuticals Archived from the original on 10 December 2017 Retrieved 5 November 2017 Medical use of cannabis and cannabinoids PDF European Monitoring Centre for Drugs and Drug Addiction December 2018 archived PDF from the original on 28 June 2021 retrieved 11 December 2019 Sapra Bani 20 June 2018 Canada becomes second nation in the world to legalize marijuana CNN Archived from the original on 12 February 2019 Retrieved 3 July 2018 Ives Mike 10 November 2022 Weed Is Now Legal in Thailand How Long Will the High Times Last The New York Times Archived from the original on 27 November 2022 Retrieved 22 January 2023 Janikian Michelle 14 September 2017 Legal Pot In Mexico Everything You Need to Know Rolling Stone Archived from the original on 11 November 2017 Retrieved 5 November 2017 Habibi Roojin Hoffman Steven J March 2018 Legalizing Cannabis Violates the UN Drug Control Treaties But Progressive Countries Like Canada Have Options Ottawa Law Review 49 2 Archived from the original on 28 August 2021 Retrieved 8 January 2021 Classification of controlled drugs European Monitoring Centre for Drugs and Drug Addiction Archived from the original on 8 January 2021 Retrieved 7 January 2021 Kaur Harmeet 2 December 2020 The UN removes cannabis from a list of the most dangerous substances CNN Archived from the original on 12 December 2020 Retrieved 7 January 2021 Kwai Isabella 2 December 2020 U N Reclassifies Cannabis as a Less Dangerous Drug The New York Times Archived from the original on 10 January 2021 Retrieved 7 January 2021 WHO recommends rescheduling of cannabis European Monitoring Centre for Drugs and Drug Addiction 25 March 2019 Archived from the original on 28 December 2020 Retrieved 7 January 2021 Georgiou Aristos 8 February 2019 WHO Recommends Rescheduling Cannabis in International Law for First Time in History Newsweek Archived from the original on 20 December 2020 Retrieved 7 January 2021 Ingraham Christopher 13 June 2017 Jeff Sessions personally asked Congress to let him prosecute medical marijuana providers The Washington Post Archived from the original on 4 July 2017 Retrieved 9 July 2017 Timothy B Wheeler 11 October 2014 Medical marijuana fees stir debate in Maryland The Baltimore Sun Archived from the original on 16 October 2014 Retrieved 12 October 2014 Blackwell Tom 16 October 2013 The pot vending machine s first foreign market Canada of course a seed for the rest of the world National Post Retrieved 4 December 2013 Uber For Weed Startup Meadow Lights Up In San Francisco TechCrunch AOL 14 October 2014 Archived from the original on 23 January 2016 Retrieved 22 January 2016 The UK is the world s largest producer of legal Cannabis UN body finds The Independent 7 March 2018 Archived from the original on 12 May 2022 Retrieved 7 December 2020 Clark Tonya Body 10 February 2015 The Medical Marijuana Debate Compliance Corner Wolters Kluwer Financial Services Archived from the original on 26 February 2015 Retrieved 26 February 2015 Peters Joey 29 June 2015 Court Employer can t block workers comp for medical marijuana NM Political Report Archived from the original on 30 June 2015 Retrieved 30 June 2015 Resolution on Medical Marijuana druglibrary org Archived from the original on 19 October 2017 Retrieved 30 July 2017 House of Delegates 2017 Resolution A8 PDF amsa org American Medical Student Association Archived PDF from the original on 1 August 2017 Retrieved 30 July 2017 Medical Marijuana Cannabis FAQs National Multiple Sclerosis Society Archived from the original on 31 July 2017 Retrieved 30 July 2017 Gattone PM Lammert W 20 February 2014 Epilepsy Foundation Calls for Increased Medical Marijuana Access and Research Press release Washington D C Epilepsy Foundation Archived from the original on 31 July 2017 Retrieved 30 July 2017 Medical Marijuana Use and Research PDF maps org Leukemia amp Lymphoma Society Archived PDF from the original on 19 October 2017 Retrieved 30 July 2017 Position Statement on Marijuana as Medicine PDF American Psychiatric Association Archived from the original PDF on 31 July 2017 Retrieved 30 July 2017 Use of Cannabis for Medicinal Purposes PDF American Medical Association 2009 archived from the original PDF on 19 October 2017 retrieved 1 July 2017 Supporting Research into the Therapeutic Role of Marijuana PDF American College of Physicians February 2016 archived PDF from the original on 3 August 2020 retrieved 1 August 2017 ASAM Issues New Public Policy Statement on Cannabis Press release Rockville MD American Society of Addiction Medicine 13 October 2020 Archived from the original on 8 November 2020 Retrieved 1 November 2020 American Heart Association 5 August 2020 Medical Marijuana Recreational Cannabis and Cardiovascular Health Circulation 142 10 e131 52 doi 10 1161 CIR 0000000000000883 PMID 32752884 Marijuana and Cancer American Cancer Society Archived from the original on 22 June 2017 Retrieved 12 July 2017 Marijuana research Overcoming the barriers American Psychological Association 14 September 2017 Archived from the original on 4 October 2017 Retrieved 9 October 2017 Arney Kat 25 July 2012 Cannabis cannabinoids and cancer the evidence so far Cancer Research UK Archived from the original on 11 February 2014 Final Rule Placement of FDA Approved Products of Oral Solutions Containing Dronabinol delta 9 trans tetrahydrocannabinol delta 9 THC in Schedule II U S Department of Justice Archived from the original on 28 March 2018 Retrieved 2 February 2018 Clark Amy 16 May 2006 New Pot Pill For Chemo Patients CBS News Associated Press Archived from the original on 28 July 2017 Retrieved 26 July 2017 Abuhasira R Shbiro L Landschaft Y March 2018 Medical use of cannabis and cannabinoids containing products Regulations in Europe and North America European Journal of Internal Medicine 49 2 6 doi 10 1016 j ejim 2018 01 001 PMID 29329891 Produkt FASS Allmanhet fass se Archived from the original on 19 October 2017 Retrieved 26 December 2013 Youssef Farid F June 2010 Cannabis Unmasked What it is and why it does what it does UWIToday Archived from the original on 17 March 2021 Retrieved 11 May 2021 McDonagh MS Morasco BJ Wagner J et al 2022 Cannabis Based Products for Chronic Pain A Systematic Review Ann Intern Med 175 8 1143 1153 doi 10 7326 M21 4520 PMID 35667066 S2CID 249433147 Archived from the original on 19 February 2023 Retrieved 19 February 2023 Further readingNational Academies Of Sciences Engineering Health Medicine Division Board on Population Health Public Health Practice Committee on the Health Effects of Marijuana An Evidence Review Research Agenda 2017 The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences Engineering and Medicine The National Academies Press doi 10 17226 24625 ISBN 978 0 309 45304 2 PMID 28182367 Archived from the original on 14 July 2020 Retrieved 7 February 2017 a href Template Cite book html title Template Cite book cite book a website ignored help nbsp External links nbsp Wikimedia Commons has media related to Medical cannabis Medical cannabis at Curlie links to websites about medical cannabis Information on Cannabis and Cannabinoids from the U S National Cancer Institute Information on cannabis marihuana marijuana and the cannabinoids from Health Canada The Center for Medicinal Cannabis Research of the University of California Medical Marijuana a 2014 2015 three part CNN documentary produced by Sanjay Gupta Marijuana and Medical Marijuana collected news and commentary at The New York Times Retrieved from https en wikipedia org w index php title Medical cannabis amp oldid 1207034203, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.